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Abstract
Next generation DNA sequencing has led to an accumulation of a putative biosynthetic gene
clusters for many natural product classes of interest. In vivo extraction and heterologous
expression do not have sufficient throughput to validate predicted enzyme functions and
inform future annotations. Further, engineering the production of new natural products
is laborious and limited by the trade-offs between cell growth and product synthesis.
Conversely, cell-free platforms, particularly those capable of cell-free protein synthesis
(CFPS), facilitate rapid screening of enzyme function and prototyping of metabolic pathways.
However, the protein content and metabolic activity of many cell-free systems are poorly
defined, increasing variability between lysates and impeding systematic engineering. Here,
the strength of untargeted peptidomics as an enabling tool for the engineering of cell-free
systems is established based upon its ability to measure both global protein abundances
and newly synthesized peptides. Synthesis of peptide natural products was found to be
more robust in purified enzyme CFPS systems compared to crude lysates; however, non-
specific peptide degradation, detected through peptidomics, remains a concern. Crude cell-
free systems were determined be better suited to small molecule production, due to the
extensive metabolic networks they were found to possess. Perturbations of these networks,
carried out through changes to growth media, were observed through shotgun proteomics and
informed engineering of phenol biosynthesis in a crude Escherichia coli lysate. Implementing
shotgun proteomics as an analytical tool for cell-free systems will increase reproducibility
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Small molecules extracted from plants, fungi and bacteria have long been valued for their
medicinal and biochemical properties. Natural products (NPs) are the compounds derived
from living sources and are among our most important natural resources. NPs account
for or have inspired between 50-70% of all pharmaceuticals and are promising biofuels,
bioplastics and pest control agents [1]. NPs were traditionally identified by activity
screening, purification and structural determination through mass spectroscopy (MS) or
nuclear magnetic resonance imaging (NMR) [2]. While low-throughput, this methodology
successfully identified numerous NPs. However, genome sequencing has revealed that
encoded in the DNA of plants and microbes are a wealth of biosynthetic blueprints to
undiscovered medicines, fuels, foods and polymers.
It has been suggested that microbes produce a wide array of natural products so they can
more readily respond to diverse stimuli [3, 4]. By changing growth conditions or providing
stressors such as competing species, microbes can be coaxed to produce natural products
[5, 6, 7]. Microbes often produce a cocktail of compounds in response to single stimuli, some
of which may already be known. Rediscovery of NPs is a hinderance to prospecting efforts
because previously discovered NPs are often produced in higher quantities and obfuscate
the detection of more novel metabolites due to their similar physiochemical properties [8].
Enabled by the development of next-generation sequencing platforms, high quality genomes
are becoming available with more microbes sequenced each year [9]. Combining this wealth
of sequence data with in vivo and in vitro characterizations of enzyme activity has allowed
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for structure and function prediction tools based on nucleotide and amino acid sequence
homology like BLAST, pFAM, and HMMER3 to become commonplace [10, 11]. Genome
mining and prediction are high-throughput but must be accompanied by experimental
validation.
The development of flexible methods for genetic manipulation of plasmid and genomic
DNA has aided the discovery of NPs and functional characterization of the enzyme which
produce them. The rapidly decreasing cost of DNA synthesis provides access to the
biosynthetic genes of difficult to culture organisms [12]. Assembly of these synthetic gene
fragments by Gibson and Golden Gate assembly allow for optimization of codon usage
and removal of inhibitory mRNA secondary structures [13, 14, 15, 16, 17]. Tools for
transformation and integration of DNA into diverse organisms have increased the range of
NPs accessible by heterologous expression [18, 19]. Furthermore, engineering of transcription
factors has facilitated activation of cryptic biosynthetic gene clusters (BGCs); this is
particularly of interest for expression of extremely large BGCs (>100 kB) that remain
prohibitively expensive to synthesize [20, 21]. Through genetic engineering previously
undescribed and ”silent” BGCs can be expressed in both endogenous and heterologous
systems [22].
In addition to its use as a tool for the exploration of BGCs, microbial metabolism can
be engineered to sustainably produce NPs and biochemicals of importance [23]. Rational
engineering strategies including enzyme engineering to remove feedback inhibition, and
improvement of substrate supply through balancing gene expression and gene knockouts of
competing pathways have grown the yield and titer of NP biosynthesis in microbes [24, 25].
Tools for prediction of optimal genetic manipulations have accelerated these efforts [26].
Additionally, stress-tolerant microbial hosts have been created by leveraging evolution for
metabolic engineering [27, 28, 29]. Recent achievements include production of anti-malarial
terpenoids in yeast, increasing yields of sustainable jet-fuel alternatives in bacteria and mixed
culture fermentation of alkaloids [30, 31, 32].
Nevertheless, in vivo validation cannot keep pace with in silico predictions as genetic
engineering and heterologous expression can be time-consuming even in model hosts.
Furthermore, NP biosynthesis can be limited by lack of NP precursor availability, toxic
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products and metabolic burden of heterologous pathways [33]. While, native NP producers
can be engineered to activate silent BGCs, non-model genetic engineering tools lack
robustness and many organisms remain recalcitrant to modification [34].
Cell-free systems are an alternative to the laborious engineering of organisms. The protein
machinery from inside living cells, extracted by a combination of lysis, fractionation and
purification, can be harnessed to carry out complex biosynthetic processes in vitro. Removal
of the cell wall and membrane and endogenous transcription and translation renders the cell
lysate as a pseudo-chemical reactor, a predominantly static network of chemical reactions
able to be added to, sampled from, and modified without genetic manipulation. Traditionally
referred to as crude lysates or cell extracts, the extracted machinery of animal and microbial
cells were important tools in the study of enzyme function prior to genome sequencing.
Rennet, the bovine stomach extract used to curdle milk, is likely one of the earliest
cell-free systems, dating back more than 6000 years [35]; rennet is now known to be
primarily comprised of chymosin, which cleaves the highly charged kappa-caesin chain
causing aggregation of uncharged micelles [36]. Early cell-free systems were uncharacterized
mixtures of proteins and metabolites extracted from a living source, that performed chemical
transformations; the identity of the numerous enzymes which collectively performed the
observed biochemical functions were not know. However by analyzing the function of these
lysates, through measurement of the consumption and production of small molecules, the
enzymes of the Kreb’s cycle, the mechanism of ethanolic fermentation in yeast and the nucleic
acid code were discovered [37, 38, 39].
Cell-free systems proved valuable for capturing the native metabolic and biochemical
functions of cellular machinery. However, without heterologous expression, the capability
of discovering and characterizing new peptides, proteins and enzymes in crude lysates was
limited. Activation of in vitro transcription and translation changed the landscape of cell-free
systems. Developed by Spirin et al. more than two decades prior to the ideation of synthetic
biology, the S100 cellular extract of Escherichia coli was capable of in vitro translation from
an mRNA template [40]. Shortly thereafter, coupled in vitro transcription and translation
was carried out from a heterologous DNA template in the crude S30 extract of E. coli [41].
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Transcription in the S30 extract is generally carried out by the viral T7 polymerase; however,
native E. coli polymerases and sigma factors have been activated as well [42, 43].
Over the following 30 years, through the tireless work of numerous researchers, the
capabilities of CFPS have grown considerably. In 2001, the Ueda lab constructed a
CFPS system from exclusively purified bacterial enzymes, which has been commercialized
as the PURE system; this system recycles tRNAs and can produce protein at a rate of
160 µg mL−1 h−1 [44]. Others have iterated upon this system increasing yield and decreasing
the costs of purification [45, 46, 47]. While the S30 lysate has the highest batch reaction
protein yield, CFPS has also been achieved across the kingdoms of life, including from wheat
germ cells [48], tobacco BY-2 cells [49], Chinese hamster ovary cells [50] and insect cells [51].
One of the greatest advantages of performing CFPS in eukaryotes is the ability to perform
post-translational modifications inaccessible to bacteria [52, 53]. With these advances, the
modern CFPS toolbox can be used to synthesize membrane proteins, perform most post-
translational modifications and reach yields of more than 2 mg mL−1 in less than 8 hours [54].
Further, with the aid of enabling technologies in microfluidics and lyophilization, cell-free
systems, in particular CFPS, are well-suited for remote and on-demand bioproduction as
remarked upon in Chapter 2.
Development of cell-free systems has not been limited to in vitro protein synthesis,
many cell-free systems have been engineered for small molecule production as well. The
crude S30 cell lysate is not only the most robust bacterial CFPS system but has also
been deployed as a platform for metabolic engineering. Cell-free metabolic engineering
(CFME) leverages the in vitro metabolic activity of enzymes and crude lysates alongside
the benefits of cell-free systems for small molecule production. The energy regeneration of
the S30 CFPS system forms the basis of many CFME efforts. Early S30 systems were
energized by regenerating ATP through consumption of a sacrificial creatine phosphate
or phosphoenolpyruvate molecule [55, 56], but greater improvements in CFPS yield were
achieved through activation of endogenous glycolytic activity producing ATP from glucose
[57]. Coupling glycolysis in crude E. coli lysate with heterologous enzymes enriched prior
to lysis or expressed by CFPS has enabled production of terpenoids, plastic precursors and
biofuels [58, 59, 60]. Compared to living systems, removal of the genome shuts down much
4
of the cell’s instructional programming and eliminates the need to cope with a continually
growing and changing system. This permits biosynthesis pathways to be engineered in vitro,
minimizing carbon and energy lost to growth.
Enabled by inexpensive synthetic DNA and heterologous expression, defined cell-free
systems for small molecule production have been constructed from purified heterologous
enzymes. Purified multi-enzyme reaction cascades have been used to synthesized terpenoids
and biohydrogen [61, 62] with high turnover rates and conversion efficiencies. Furthermore,
purified enzymes have been used to create new biochemical functions, that would be toxic
in vivo, such as a molecular purge value that balances concentration of NAD+ and NADP+
[63]. In contrast to crude lysates, all metabolic activity in defined systems must be assembled
from purified enzymes. While they have many advantages, the size and number of metabolic
pathways that are feasible to simultaneously activate in a defined system is strictly limited
by the expensive and time-consuming purification of its protein components [64].
That lack of this requirement is one of the greatest strengths of crude cell-free systems;
however, this trade-off is not without costs as most crude cell-free systems are a black
box - a system with largely undefined components. Numerous variables impact the
metabolic potential of crude lysates and few have been empirically optimized (Figure 1.1.
Notably, while the S30 crude CFPS system is among the most commonly used lysates,
the impact of the numerous improvements to its preparation on the protein complement
of the lysate are unknown [65, 66]. For example, inorganic phosphate is included its
preparation media to reduce kinase activity; however, downregulation of kinases has not
been observed experimentally [67]. Furthermore, there are an abundance of published
preparation protocols, but standards for benchmarking are poor - frequently consisting solely
of expression of fluorescent proteins and mRNA aptamers.
A promising alternative method for characterization of crude cell-free systems is shotgun
proteomics; in this process, protein mixtures are enzymatically digested, and the resulting
peptides are separated through reverse-phase liquid chromatography and sequenced with
tandem mass spectromtery [68]. By measuring the abundance of the peptides which make
up each protein, this un-targetted method provides comparative abundance measures of
both the protein machinery of the cell-free system and of newly synthesized proteins. This
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Figure 1.1: Cellular growth stage and harvest timing impact both cellular protein content
and the proteome of the resulting cell lysate. The S30 lysate is harvested at early exponential
phase to maximize ribosome concentration and in vitro protein synthesis capacity
method is made possible through advances in bioinformatic data analysis tools for predicting
peptide MS/MS spectra from genomic data and matching them to observed spectra [69].
Additionally, coupling the high scan rate of quadrupole mass analyzers with high mass
accuracy analyzers in quadrupole-Time-Of-Flight and quadrupole-orbitrap instruments has
increased the number of peptides that can be identified in a single run. Nevertheless, it is
important to consider that an observed increase or decrease in abundance of a protein is
not equivocal with up- and down-regulation of that protein; many non-regulatory factors
including degradation, digestion efficiency and sample composition can impact observed
protein abundance.
Shotgun proteomics excels at identification of highly abundant proteins; however the
presence of peptides of highly abundant proteins can interfere with identification of lower
abundance proteins and limits the dynamic range of this method. These impacts are less
prevalent in samples with lower complexity and can be offset by improved fractionation
and chromatography methods [70]. This makes shotgun proteomics particularly robust for
measuring protein abundances in bacteria, which have small genomes with few peptides
shared among proteins. Its application is well-suited to crude bacterial cell-free systems as
lysis has already been uniformly performed and most of the dynamic regulation present in a
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cell is eliminated. With the application of omics tools such as shotgun proteomics, iterative
and rational engineering of crude cell-free systems is possible.
1.0.1 Research Aims
The unique ability of cell-free systems to carry out complex biochemistries, including
some inaccessible to living cells, while mimicking the cellular environment makes them an
important tool to synthetic biology efforts to explore, understand and engineer metabolic
processes. The high-throughput in vitro expression of enzymes made possible by CFPS
enables cell-free systems to be used to discover new natural products, engineer new
metabolisms and to produce biocommodities at scale [71]. However, improved analytical
tools must be employed to systematically engineer lysates and monitor reaction progress.
The goal of this dissertation is to detail the development and use of a systems metabolic
engineering approach to the discovery, production, and characterization of small molecules
in crude cell-free systems.
CFPS is the most robust and well-researched function in cell-free systems. The
recent successes of cell-free protein production as a research tool and as a platform for
synthesis of biologics at the point-of-care are reviewed in Chapter 2. The many advantages
to cell-free bioproduction have driven interest in cell-free platforms for small molecule
production; however, these systems require additional development and optimization to
reach the productivity of CFPS. The remainder of this work focuses on expanding cell-
free bioproduction to two small molecule classes – products derived from endogenous E. coli
metabolism and peptidic NPs.
Chapter 3 and chapter 4 focus on the investigation and engineering of the biosynthetic
potential of endogenous metabolism in crude E. coli cell lysates. These works develop
shotgun proteomics as an enabling technology for engineering cell-free systems with an
emphasis on small molecule production. In chapter 3 the impacts of growth condition
variables on the enzymes involved in pyruvate synthesis are revealed through shotgun
proteomics. Chapter 4 expands upon this approach by employing shotgun proteomics to
guide modifications to a defined crude lysate preparation media for increased production of
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aromatic amino acids in vitro. These works demonstrate the power of omics-scale analytical
techniques for elucidating the metabolic black box of cell-free systems.
Chapter 5 focuses on the expansion of CFPS to the production of peptidic NPs in cell-
free systems. For the investigation of lasso peptide BGCs in the Populus root microbiome,
a methodology was developed pairing cell-free peptide synthesis with untargeted peptide
sequencing by LC MS/MS to monitor the production and tailoring of ribosomally synthesized
and post-translational modified natural products. This work highlights the need for more
comprehensive measures of protein and polypeptide synthesis in cell-free systems, which
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2.1 Abstract
Protein drugs, or biologics, are a growing emphasis for the pharmaceutical industry owing
to their unparalleled potency and specificity. Due to their temperature sensitivity, however,
storage and distribution remain challenges. Furthermore, industrial scale production of
biologics is not well matched to the needs of personalized medicine. To take full advantage of
the potential of biologics, new methodologies for their synthesis and purification are required
to produce them when and where they are needed most – at the point of care. Cell-free
protein synthesis possesses the requisite portability and versatility to meet these needs.
Recent innovations that are leading to distributed production techniques, enhanced product
yields, and custom modifications will enable the rapid, on-demand production of personalized
medicines.
2.2 Article
The functional diversity of proteins is astounding. Proteins can selectively organize, bind
or catalyze a vast array of substrates. Living systems are enabled by these capabilities
and various applications benefit from their engineered production. For example, protein-
based pharmaceuticals, or biologics, have grown in popularity since the development of
biosynthetic human insulin in 1978. Currently, biologics include some of the most highly
prescribed drugs, including Humira for treating autoimmune diseases and Epogen/Procrit for
addressing anemia resulting from renal failure and chemotherapy. Biologics are the fastest
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growing sector of the pharmaceutical industry and their advantages over small molecule
drugs ensure continued development [72]. These advantages include; i) unmatched potency,
ii) potentially lower toxicity and iii) a broader diversity of targets for which they are selective
[73].
Advances in genetically engineered organisms allow economical production of biologics.
Often, microbial systems are employed due to their fast growth and genetic tractability.
Currently, over a third of biologics are produced from genetically-modified microbes such as
S. cerevisiae and E. coli [74]. Further, modern genetic construction and cloning techniques
facilitate the discovery and development of strategies for the biosynthesis of novel biologics
[73]. These genetically engineered microbial processes can be scaled-up to large batch
cultures capable of manufacturing biologics with yields up to 7 g/L [75]. As optimization
tools for genetic and metabolic engineering progress, the time and costs associated with
developing new biologics are reduced.
Producing and distributing biologics comes with challenges. Unlike many small molecule
drugs, biologics can be expensive to manufacture and temperature sensitive, causing a
reduced shelf-life. While storage and distribution rarely present problems for advanced
medical facilities, use in under-developed communities and remote environments is challenged
by the need for uninterrupted cold storage. Maintaining protein activity until use may
demand alternative approaches for preparing biologics. For example, if the material can be
manufactured at its point of need, storage and distribution requirements can be minimized.
Living cells are well suited for large-scale production. However, maintaining cell viability
until use is not practical. In contrast, cell-free approaches for preparing biomolecules can
overcome this limitation. This technique utilizes the protein machinery extracted from cells
to carry out complex biosynthesis processes. For example, the transcription and translation
machinery can be used to synthesize a chosen protein, or metabolic capabilities can be
activated, or created, to prepare a metabolic compound. Potentially, cell extracts can
be stored as universal reagents capable of transforming simpler reagents into a diverse
range of biologics. Through selection and addition of a DNA sequence, and a mixture
of shelf-stable reagents, potentially any desired protein can be created. While approaches
for maintaining optimal activity of cell extracts require further investigation, transitioning
11
to a universal reagent set would maintain versatility and dramatically reduce needs for
cold storage. Further, use of lyophilized cell extracts has been demonstrated, which could
facilitate long-term reagent stability [76].
The usefulness of cell free methods matches other emerging needs in medicine. As DNA
sequencing costs drop, a paradigm shift in medicine is occurring with the goal of tailoring
treatments to a patient’s genetic make-up. Individualized biologics, personalized to the
unique needs of the patient, have been proposed for treating disease [77]. While large-batch
industrial production of biologics has been sufficient for generally applicable pharmaceuticals,
a flexible production strategy will be necessary to accommodate the rapid personalization
of medicine. Feasibly, the quantity of a custom biologic needed for a single dose can be
prepared by cell free protein synthesis (CFPS) in a portable format allowing remote, personal
production of pharmaceuticals for specialized and emergency situations.
To advance CFPS for rapid, on-demand production of biologics, the product yield of
the reaction must be improved. Reaction performance depends on the cell extract that is
chosen. Cell extracts can be isolated in numerous ways, and from a variety of organisms. At
the highest level, these extract preparation methods can be separated into two categories:
purified and crude extracts. Purified extracts include one-pot reaction cascades carried out
by combinations of purified enzymes and cellular machinery [44, 78]. These well-defined
extracts reduce the number of potential side products and can simplify product clean-up
steps; however, the upfront enzyme purification steps may render these extracts too costly
for purposes other than research and development. In contrast, crude extracts are made
from the lysis of whole cells. Native nucleic acids, membranes and metabolites are removed
and the remaining cellular machinery is resuspended in a solution of salts, buffers and
cofactors necessary to carry out bioprocesses. Extracts from both eukaryotic and prokaryotic
cell lines have been used for carrying out in vitro bioprocesses [79, 80, 81]. Prokaryotic
systems, namely E. coli, are the most advanced, and ongoing efforts in strain engineering
and energy regeneration systems have improved protein synthesis yields [82, 83]. Typically,
protein synthesis reactions are complete within a few hours. Bacterial extracts, however,
cannot carry out all of the steps necessary to synthesize functional eukaryote-derived and
post-translationally modified proteins without additional enzymatic processing. In contrast,
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common eukaryotic wheat-germ, rabbit reticulocyte and insect cell free expression systems
are capable of particular protein modifications; however, they lack the strain engineering
tools and high protein yields offered by E. coli extracts. Continued efforts in genome wide
engineering of cell extract source strains through CRISPR, MAGE and TRMR have increased
mRNA and protein stability and enabled new functions [47]. The development of robust
cell free protein expression in other cell extracts, or appropriate modifications of bacterial
extracts, is needed for effective production of biologics.
The potential for producing therapeutically useful amounts of proteins in a portable
format is becoming increasingly feasible. Typical requirements for therapeutic proteins
dosages range between 0.01 to several milligrams per day [84]. For comparison, highly
productive E. coli strains lead to cell free protein synthesis yields, in batch mode, of more
than 2 mg/mL [54]. Further, it has been demonstrated that protein synthesis in microfluidic
formats can improve yields by more than 6 fold compared to traditional batch reactors [84].
These efforts are critical to enabling portability, and when combined with high-yield extracts,
can make remote production of useful amounts of biologics possible. However, similar to cell-
based bioprocesses, proteins derived from cell-free systems need additional purification in
order to be usable in a therapeutic context. Cell free synthesis approaches alleviate the need
for cell lysis and related processing steps allowing the reaction products to be directly applied
to chromatography columns. Microfluidic versions of common protein separation techniques
have also been demonstrated [85]. Modular combinations of purification procedures, such
as affinity binding, anion exchange and protein desalting, can potentially be configured
to isolate a variety of desired products in a miniature format. Complementary tools for
assessing protein quantity, activity, and purity at the microscale are needed. Development
of these tools is promising as they share many of the same challenges as point-of-care
diagnostics, which have enjoyed steady improvements in the analysis of proteins, nucleic
acids and complex biological samples [86]. Nevertheless, the tools and technology for rapid,
portable production of proteins are bringing on-demand biologics closer to reality.
With advances in on-demand biologics, other technical applications become feasible.
Cell free approaches can also produce enzymatically active proteins. Functional metabolic
pathways can be reconstructed from purified enzyme products, or possibly produced in
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situ by CFPS, to prepare valuable commercial and therapeutic small molecules (e.g.,
antibiotics, vitamins, dyes, and pest control compounds) [62]. Beyond use in remote or
resource challenged settings, cell-free biosynthesis is capable of facilitating various avenues
of basic research; miniaturized and high-throughput proteomics for diagnostics, prototyping
of biosynthetic pathways for eventual scale-up or analysis of genetic networks for synthetic
biology can be considered [87]. Further, preparation of any of the large number of
unknown proteins identified by genome sequencing efforts can facilitate understanding of
their functional roles and can benefit from microfluidic-based approaches to determine their
binding partners [88, 89].
The ease of implementing protein synthesis and purification at reduced scales, coupled
with the constantly decreasing costs of gene synthesis, will expand the reach of cell free
technologies and facilitate its use by small businesses, schools, and enterprising individuals,
similar to the now-widespread adoption of additive manufacturing in the Maker community.
Comparable to 3D printing, cell free techniques can accommodate niche and diverse markets
due to low start-up costs and decreasing barriers to entry compared to traditional large-
scale bioprocesses. As with most democratized technology, there are issues that will need to
be addressed regarding regulations, intellectual property and biosafety; but, many of these
issues are already under consideration by the scientific and regulatory communities with
regards to synthetic biology.
Cell-free protein synthesis exploits the efficiency and versatility of biological processes
without the limitations that come with managing living organisms. With the aid of
micro- and nano-fluidic technologies, this technique can produce diverse biomolecules at
therapeutically relevant scales. Furthermore, the absence of requirements for cell viability
makes this technique ideal for the on-demand and customized synthesis of biologics at the
point-of-care. Continued development and integration of the underlying technologies can
enable rapid, convenient access to the functional diversity of proteins.
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Chapter 3
Elucidating the potential of crude cell
extracts for producing pyruvate from
glucose
15
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3.1 Abstract
Living systems possess a rich biochemistry that can be harnessed through metabolic
engineering to produce valuable therapeutics, fuels and fine chemicals. In spite of the
tools created for this purpose, many organisms tend to be recalcitrant to modification or
difficult to optimize. Crude cellular extracts, made by lysis of cells, possess much of the
same biochemical capability, but in an easier to manipulate context. Metabolic engineering
in crude extracts, or cell-free metabolic engineering, can harness these capabilities to feed
heterologous pathways for metabolite production and serve as a platform for pathway
optimization. However, the inherent biochemical potential of a crude extract remains
ill-defined, and consequently, the use of such extracts can result in inefficient processes
and unintended side products. Here, we show that changes in cell growth conditions
lead to changes in the enzymatic activity of crude cell extracts and result in different
abilities to produce the central biochemical precursor pyruvate when fed glucose. Proteomic
analyses coupled with metabolite measurements uncover the diverse biochemical capabilities
of these different crude extract preparations and provide a framework for how analytical
measurements can be used to inform and improve crude extract performance. Such informed
developments can allow enrichment of crude extracts with pathways that promote or deplete
particular metabolic processes and aid in the metabolic engineering of defined products.
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3.2 Introduction
Synthetic biology aims to manipulate and exploit the existing biochemical functions of livings
organisms for desired purposes. Unfortunately, efforts to engineer these systems to unlock
their diverse metabolic potential require developing clever methodologies to overcome aspects
of the machinery that the organism uses for survival. In vitro synthetic biology offers an
alternative way to harness an organism’s rich metabolism; it is driven by the prospect of easy
to manipulate, static systems (Smith et al., 2014). Livings cells require membranes, energy
and building blocks for growth, and dynamic regulation of their biochemical processes. By
removing the requirement to sustain life, in vitro systems can sidestep many of the barriers
to manipulation and present an ideal system for metabolic engineering.
In their most basic form, in vitro systems for metabolic engineering lack the genetic
material and membranes inherent to a living system. Such in vitro, or cell-free metabolic
engineering (CFME), approaches enable the use of techniques usually reserved for chemical
engineering approaches such as continuous reaction monitoring, allowing for greater control
over enzymes and metabolite concentrations [80, 90]. Coupled with systems biology tools
for flux balance analysis and elementary mode analysis, in vitro systems present a potent
platform for bioproduction [91]. The absence of a cell wall and membrane facilitates the
exchange of substrate to, and product from, the system and simplifies reaction work up.
Removal of the genome shuts down much of the cell’s instructional programming and
eliminates the need to cope with a continually growing and changing system. This enables
biosynthesis pathways to be engineered in vitro, minimizing carbon and energy lost to
growth. Additionally, this minimizes the management of feedback regulation and allows
for the production of metabolites that would be toxic to intact cells [92].
Ideally, a cell-free metabolic engineering system would contain only the components
necessary to carry out the desired biochemical process. One promising approach for
complex chemical conversion uses a defined set of purified enzymes. This methodology
has been successfully demonstrated for hydrogen production and protein synthesis among
others[44, 93]. While recent efforts in co-purification of full reaction cascades have reduced
costs, any process utilizing bulk purified proteins remains expensive [94, 47]. To date, the use
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of purified components for CFME has resulted in long running systems capable of catalyzing
reactions for several days, but with the drawback of slow catalysis rates. Novel work by
Korman et al. on the production of limonene showcases the strengths and limitations of this
approach [61]. Additionally, optimization of purified systems depends on ample information
about the pathway and the involved proteins. These methods may fail to include accessory
proteins which can improve pathway yield.
Crude cell extracts are finding increasing applications as alternatives to purified enzyme
systems for metabolic engineering. Cell growth, followed by lysis and minimal fractionation
can rapidly create robust biochemical systems for a fraction of the cost of purified
enzymes. These systems contain the same enzymes and much of the same biochemistry
as living systems and can serve as a proxy for the engineering of metabolite production
by conventional, in vivo metabolic engineering. Recent work has demonstrated crude
extracts as a platform for bioproduction as well, due to reduced costs of scale up and
their compatibility with traditional chemical reactors [95, 96]. Further, early work in the
optimization of bacterial cell free protein synthesis (CFPS) systems demonstrated the ability
of crude cell extracts to energize translation in vitro through the consumption of glucose or
other glycolytic intermediates [57, 97]. Glucose conversion is accomplished through the 10-
step enzymatic process of glycolysis starting with the phosphorylation of glucose to glucose-
6-phosphate and producing ATP through a series of substrate level phosphorylations. As
shown in the aforementioned works, crude E. coli extracts can metabolize low-cost feedstocks
like glucose to provide key intermediates and energy that can be drawn upon for myriad
applications. The limits of the flexibility of crude extracts, granted by their inherently
diverse biochemistry, remain uncertain. The proteome that enables these capabilities is only
beginning to be explored and the extract preparation variables that influence this proteome
require illumination [98]. Proteomic analyses coupled with metabolite measurements can be
used to identify and characterized the biochemical pathways capable of being supported by
crude extracts.
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3.3 Materials and methods
3.3.1 Cell-free extract preparation
Cell extracts were prepared from E. coli BL21 Star (DE3) grown at 37 ◦C in one of
three media: M9-fructose (11.1 mg l−1 CaCl2, 0.120 g l
−1 MgSO4, 4.0 g l
−1 fructose, 0.15 g l−1
KH2PO4, 3.39 g l
−1 Na2HPO4, 0.25 g l
−1 NaCl, 0.5 g l−1 NH4Cl); lysogeny broth (LB: 10 g l
−1
tryptone, 5 g l−1 yeast extract, 10 g l−1 NaCl); or 2xYPTG (16 g l−1 tryptone, 10 g l−1 yeast
extract, 5 g l−1 NaCl,7 g l−1 KH2PO4, 3 g l
−1 K2HPO4, 18 g l
−1 glucose). The extracts
prepared from these media are referred to as, DF, LB, and YT, respectively. Cell extracts
were prepared by harvesting 50-mL cultures grown in baffled Erlenmeyer flasks to an OD600
of 1.0 for DF, 2.0 for LB, or 4.0 for mid-log phase YT (YT-M). The DF cells were additionally
transferred to M9 salt solution containing no fructose for 24 hours before harvesting. A
second-type of YT extract, YT-E, was prepared by growing cells to an OD600 of 2.8
and harvesting. Cells were harvested by centrifugation at 5000x g for 10 min in 50 mL
volumes and washed twice with S30 buffer (14 mM magnesium acetate, 60 mM potassium
glutamate, 1 mM dithiothreitol (DTT) and 10 mM Tris-acetate, pH 8.2) by resuspension
and centrifugation. After the final centrifugation, pellets were weighed, flash-frozen in liquid
nitrogen and stored at –80 ◦C. For extract preparation, cells were thawed and resuspended
in 0.8 mL of S30 buffer per mg of cell wet weight before sonicating using 530 joules per mL
of suspension at 50% tip amplitude with ice water cooling. After sonication, the cell-slurry
was centrifuged twice for 10 minutes at 21,100 x g at 4 ◦C, aliquoted, flash-frozen and stored
at –80 ◦C.
3.3.2 Cell-free reactions
Cell free glucose conversion reactions were carried out at 37 ◦C for 24 hours in 25 µL volumes
with a final concentration 250 mM glucose, 18 mM magnesium glutamate, 15 mM ammonium
glutamate, 195 mM potassium glutamate, 1 mM ATP, 150 mM Bis-Tris, 1 mM NAD+, 10
mM dipotassium phosphate. Pyruvate consumption reactions were carried out using the
same conditions and reagents, with the exception of glucose being replaced with 25 mM
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pyruvate. Growth enriched extracts were added to a final protein concentration of 4 mg mL−1.
The reactions were quenched by the addition of an equal volume of 5% trichloroacetic acid.
The supernatant after centrifugation at 11,000 x g for 15 minutes was used for analytical
measurements.
3.3.3 Analytical measurements
High-performance liquid chromatography (HPLC) was used to measure pyruvate and glucose
in the cell-free reactions. An Agilent 1260 series HPLC system equipped with a diode array
UV-visible detector (Agilent, Santa Clara, CA) reading at 191 nm, with an Aminex HPX
87-H column (Bio-Rad, Hercules, CA) was used for the quantifications. Analytes were eluted
with isocratic 5 mM sulfuric acid at a flow rate of 0.55 mL/min at 35 ◦C for 25 min.
3.3.4 Proteomics
CFME extracts were denatured with 6 M guanidinium chloride for 1 h at 60 ◦C and
allowed to cool to room temperature. Cysteines were reduced by incubation in 2 mM
tris(2-carboxyethyl)phosphine hydrochloride (TCEP) for 20 min at room temperature and
carboxamidomethylated by incubation in 10 mM iodoacetamide in the dark for 15 min.
Samples were diluted with 5 volumes of digestion buffer (50 mM Tris-HCl, 10 mM CaCl2,
pH 7.6), and the proteins were digested by adding trypsin at a 1:50 weight ratio (based
on Bradford assay) with overnight incubation at 37 ◦C. An additional identical amount
of trypsin was then added, with an additional 4 h incubation at 37 ◦C. Trypsin was
inactivated by addition of formic acid to a final concentration of 0.1%. Tryptic peptides
were obtained by centrifugation through a 10 kDa molecular weight cutoff filter (Microcon
YM-10, Millipore, Billerica MA) for 20 min at 14,000 x g. 50 µg of tryptic digests were
loaded onto a strong cation exchange resin (SCX) (Luna, Phenomenex, Torrance, CA) and
desalted. Digests were analyzed by two-dimensional liquid chromatography-tandem mass
spectrometry [99]. Briefly, peptides were eluted from SCX resin with an eleven-step gradient
of aqueous ammonium acetate (50 mM to 500 mM) onto reverse-phase C18 resin (Aqua,
Phenomenex, Torrance, CA). Peptides were eluted from reverse-phase over two hours with
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a gradient from 100% solvent A (5% CH3CN, 0.1% formic acid in water) to 50:50 solvent
A: solvent B (70% CH3CN, 0.1% formic acid in water). Peptides eluted from the column
were introduced into the linear ion trap mass spectrometer (LTQ-XL, ThermoScientific)
by nanoelectrospray. Peptide identifications were obtained from MS/MS spectra using the
program Myrimatch (version 2.1.138) and compared against the Escherichia coli BL21
(DE3) proteome (UP000002032), and protein identifications were assembled from peptide
identifications using IDPicker, version 3.1.599 [100, 69]. KEGG Orthologies and Enzyme
Commission numbers were assigned by BlastKOALA [101]. Full tables of detected proteins,
tryptic peptides and KEGG orthology assignments are deposited in Supplemental Table
A-1 and Supplemental Table A-2. Descriptions of these tables and their legends are
supplied in Supporting Information.
3.3.5 Statistical analysis
Three biological replicates were used for all HPLC measurements. Error bars in figures
represent ± 1σ. Proteome analyses were likewise performed on three biological replicates.
Significant changes in protein abundance for a given pair of treatments were identified
using T-tests (2-tailed, unpaired, equal variances) on log10-transformed normalized spectral
abundance factor (NSAF) value, with Benjamini-Hochberg correction for multiple hypothesis
testing. Differential abundance was determined by ANOVA and direction of regulation by
comparisons of prevalence value as previously described [98]. Gene set enrichment analysis
(GSEA) was performed using the tools designed by Subramanian et al. [102]. In brief GSEA
was performed using gene ontology (GO) terms and Uniprot pathway and superpathway
annotations as pairwise comparisons of log10 transformed NSAF values between each set of
extracts. Gene sets enriched with a false discovery rate < 25% were retained.
3.4 Results
Given that the metabolic capabilities of a cell-free extract result from the active proteome,
we hypothesized that changes to growth conditions prior to preparation of cell extracts
would create shifts in the protein content and the resulting metabolic abilities of the crude
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extracts. With the goal of investigating the protein elements of crude cell extracts that
influence precursor supply, pyruvate biosynthesis in crude extracts was assessed. Pyruvate
is both an important compound central to carbon metabolism, linking glycolysis and Krebs
cycle and a launching point for numerous biotechnological targets [103]. Proteome profiles
were obtained for the resulting crude extracts and validated by measuring the extracts’
ability to produce pyruvate after the addition of glucose.
The effects of four growth conditions on the protein content and metabolic ability of E.
coli crude extracts to produce pyruvate from glucose, were assessed. Three different growth
media were used: standard rich broth (lysogeny broth, LB), M9 minimal medium with
fructose (deprived fructose, DF), and extra-rich broth (2xYTPG, YT) with cells collected
at mid-log phase. Cell growth in the 2xYPTG medium saturates at an OD600 of 8-10.
Cells grown in this media were collected at both early, (OD600 2.8) and mid-log phase
(OD600 4.0), and are referred to as YT-E and YT-M, respectively. The 2xYPTG condition,
collected in early-log phase growth, is commonly used for CFPS [104]. Cells collected early
in log phase growth have the greatest specific growth rate, a parameter that is suggested to
influence CFPS capabilities and may affect the abundance of glycolytic enzymes [105, 106].
These growth conditions were chosen based on variables with the potential to enrich for
glycolytic enzymes and for their frequent use for bacterial growth and related experiments
that employ crude cell extracts. The DF condition employed M9 medium with fructose
as the carbon source and a starvation regimen, which is reported to increase expression of
glycolytic enzymes [107].
3.4.1 Effects of Growth Conditions on Proteomes of Extracts
Three biological replicates of the chosen cell extracts were digested with trypsin, and tryptic
peptides were analyzed using multidimensional protein identification technology (MudPIT)
as previously described [99]. Proteins were identified and assigned functions by matching
peptides against an E. coli BL21 (DE3) genome that had previously been annotated by
KEGG’s BlastKOALA software [101]. After removal of low abundance proteins and data
filtering, 1170 unique proteins were identified across all four conditions, with a core set of
796 proteins present in all four conditions. Despite overlap in media components between
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several of the growth conditions, there were measurable differences in the proteomes of the
four resulting cell-extracts. Excluding YT-M, each growth condition contained at least 10
unique proteins (Figure 3.1). As the same 2xYTPG media is used for both the YT-M and
YT-E conditions the conditions overlap strongly, a larger number of proteins (40) are shared
and are distinct from the LB and DF conditions. Further, the rich media conditions (LB,
YT-E, YT-M) share a large number of proteins (132) that are distinct from the minimal
media based DF condition.
With the goal of characterizing the proteins contributing to pyruvate production, the 10
enzymes comprising glycolysis were analyzed. In E. coli, four of the glycolytic enzymes exist
as isoforms; 6-phosphofructokinase (Enzyme Commission (EC) number 2.7.1.11), glycerol-
3-phosphate dehydrogenase (1.2.1.12), phosphoglycerate mutase (5.4.2.12), and pyruvate
kinase (2.7.1.40), which may be regulated and function differently in a living cell. As the
origin of these differences is beyond the scope of this work, each enzyme group is henceforth
represented functionally as an EC number shared within isoforms. At least one isoform of
each of the 10 glycolytic enzymes is present in all 4 conditions (Figure 3.2). While glycolysis
Figure 3.1: Venn diagram representing proteins found in each of the four growth conditions
after filtering out low abundance proteins. There is a core set of 796 proteins present in all
four conditions. The different conditions contain a small number of unique proteins, with
the exception of YT-M, which may be a subset of the YT-E conditions. The cell extracts
grown in rich media (YT-E, YT-M, LB) share a greater number of proteins (132) than any
other subset of these conditions.
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Figure 3.2: A.) Proteomic assessment of the potential in vitro metabolic fates of glycolytic
intermediates. Enzymatic steps are represented by Enzyme Commission (EC) numbers.
Each EC number and reaction arrow corresponds to at least one protein detected in all
growth conditions. Upregulated steps are represented by red, green, orange and blue colored
arrows for YT-E, YT-M, DF, and LB growth conditions, respectively. Only differentially
abundant sinks of glycolytic intermediates are shown. Cofactors are depicted as colored
circles, full yellow circle, ATP; half yellow circle, ADP; full blue circle, NADH; half blue
circle, NAD+; “Pi” within the empty circle, inorganic phosphate. B.) Phosphoenolpyruvate
transferase system reaction schematic. General PEP phosphotransferase enzyme, EI, is
upregulated in both the YT-E and DF cell extracts. HPr phosphotransferase protein and
glucose-specific IIA protein are only present in YT-E condition. Enrichment is represented
by NSAFs.
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is predominantly regulated through allosteric interactions, differences in abundance of the
participating enzymes may also affect flux through the pathway [108]. As shown in (Figure
3.2), three enzymes within glycolysis are upregulated in the DF condition (1.2.1.12, 4.2.1.11,
and 2.7.1.40).
In addition to energy, glycolysis provides the metabolic feedstocks for many important
pathways, including the pentose phosphate pathway and the Krebs cycle, which in turn are
the source of the carbon backbone for most primary and secondary metabolites in bacteria.
The many carbon sinks leading out of glycolysis represent a significant draw away from
pyruvate production. To account for the effect of these pathways, abundances of every
enzyme in the BL21 (DE3) genome known to interact with an intermediate or product
of glycolysis were analyzed for differences. These results are compiled in Supplemental
Table A-3. Figure 3.2 depicts the key differentially abundant enzymes in the cell
extract proteomes that can act on glycolytic molecules. In particular, the pathway to
the aromatic amino acid precursor shikimate was differentially represented via the pentose
phosphate pathway enzyme transaldolase (2.2.1.2) and 3-deoxy-D-arabino-2-heptulosonic
acid 7-phosphate (DAHP) synthetase (2.5.1.54).
The 10-enzyme glycolytic pathway from glucose to pyruvate begins with a phosphory-
lation that can be performed by hexokinase (2.7.1.2). This enzyme is present in all four
extract conditions, but the phosphoenolpyruvate phosphotransferase system (PTS) provides
an alternative entry point into glycolysis. PTS is a multi-protein phosphorylation cascade
that in vivo results in a phosphorylated sugar moiety using PEP as an energy source.
Previous work in vitro has demonstrated activity of the glucokinase and PEP phosphatase
enzymes in crude extracts [109]). PTS specificity is dictated by the non-membrane bound
IIA enzyme and membrane-bound IIBC enzyme, which often will only phosphorylate a single
sugar, allowing for selective import of dedicated sugars. The EI PTS protein is upregulated
in both the YT-E and DF extract (Figure 3.2). While the DF extract condition contains
the fructose/mannitol-specific IIBC protein, the YT-E extract proteome uniquely contains
the glucose-specific IIBC enzyme.
Analysis of individual enzymes helps to predict the flow of carbon through a cell extract.
However analysis of individual abundances may fail to detect systematic differences between
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cell extracts. Sets of phenotypically related genes can be co-regulated, but individually fail
pairwise tests of significance. GSEA was performed using GO terms and Uniprot pathway
designations annotated with the genome to account for these differences [102]. GSEA was
performed as pairs of comparisons but some enrichments were shared amongst different
comparisons and were consolidated (Table 3.1).
3.4.2 Pyruvate Production
We first investigated the glycolytic activity of the differentially prepared crude extracts by
introducing them to a standard reaction mixture of the necessary co-factors NAD+ and
ATP as well as a set of buffering reagents and salts in order to confirm their ability to
consume glucose and drive glycolysis towards pyruvate production. Over the course of a
24-hour incubation, aliquots of each reaction were halted using TCA, and quantified for
glucose by HPLC analyses. Each extract broke down different amounts of glucose with YT-
E consuming the largest amount at 147 mM at an average rate of 6.75 mM l−1 over a 24
hour period (Figure 3.3).
The concentration of pyruvate was simultaneously analyzed along with glucose consump-
tion for each of the prepared extracts over a 24-hour time period. As would be expected, the
final concentrations of pyruvate complemented the consumption rate of glucose with the YT-
E extract producing the greatest amount of pyruvate at 21.29 mM. The DF extract produced
the least amount of pyruvate at 0.73 mM and the values for LB and YT-M fell in between.
However, the conversion of glucose to pyruvate was not quantitative. The differences in
the extract’s ability to both consume glucose and produce pyruvate, implies that CFME
extracts can have a variety of metabolic capabilities based on their different protein content
that results from changes in the cell growth conditions.
Due to the breadth of potential metabolic pathways present in the crude extract, we next
sought to understand if the presence of the targeted metabolite, pyruvate, was maintained at
a sufficient level to be an adequate feedstock for subsequent metabolic conversion. To test the
activity of the extract’s downstream pyruvate consumption pathways, we exogenously added
pyruvate and co-factors to each extract and measured total pyruvate consumption after a
24-hour period (Figure 3.4). As suggested from the proteomic analyses, sink pathways for
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Table 3.1: Summary of gene set enrichment analysis results based on biological process and
molecular function GO terms and Uniprot Superpathway annotations. Table represents all
enrichments found with a false discovery rate < 25% in pairwise comparisons. Enrichments
found in more than one comparison have been combined.
Condition Enrichment Description Direction of regulation Comparison
YT-E Carbohydrate Metabolism Down LB,DF
YT-M Purine Metabolism Up YT-E
YT-M Cofactor Biosynthesis Up YT-E
DF Amino Acid Biosynthesis Up YT-E,LB
DF Carbohydrate Degradation Up LB
DF GO:0000049 tRNA Binding Down YT-M, YT-E
DF GO:0003676 Nucleic acid
binding
Down YT-M, YT-E
DF GO:0003723 RNA binding Down YT-M, YT-E
DF GO:0003735 Ribosome Down YT-M, YT-E
DF GO:0005506 Iron ion bind-
ing
Down YT-M, YT-E




DF GO:0006281 DNA Repair Down YT-M
DF GO:0006412 Translation Down YT-M, YT-E
DF GO:0006457 Protein Folding Down YT-M, YT-E,
LB
DF GO:0007049 Cell Cycle Down YT-M, YT-E,
LB
DF GO:0019843 rRNA binding Down YT-M, YT-E

















DF GO:0050661 NADP Binding Up YT-M
DF GO:0051287 NAD binding Up YT-M
LB GO:0030170 pyridoxal phos-
phate binding
Up YT-E








Figure 3.3: Extracts are shown here as orange, blue, green and red colored symbols and lines
for DF, LB, YT-M and YT-E growth conditions, respectively. Data and standard deviation
for the time course reactions were acquired using n=3 biological replicates. Glucose and
pyruvate were simultaneously measured at various time points over a 24-hour period. Solid
lines indicate glucose time courses and dashed lines indicate those for pyruvate.
Figure 3.4: Extracts are shown here as orange, blue, green and red colored symbols and
lines for DF, LB, YT-M and YT-E growth conditions, respectively. Data and standard
deviation for the pyruvate substrate reactions were acquired using n=3 biological replicates.
The extracts’ ability to consume exogeneous pyruvate was measured. Time 0 h indicates
initial pyruvate concentration. Final concentration is measured after 24 h.
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glycolytic intermediates are well represented in the crude extracts. Calculation of the glucose
to pooled pyruvate conversion rates and the pyruvate consumption rates indicate significant
differences in the fraction of glucose that passes through pyruvate (Table 3.2). Each of the
extracts was capable of consuming a large portion of the pyruvate provided regardless of the
extract preparation condition. The YT-M extract was capable of consuming pyruvate at
nearly the same rate as the YT-E extract, 0.96mM l−1 and 0.93mM l−1 respectively, despite
the YT-E extract producing a larger pool of pyruvate after 24-hours.
The DF condition was capable of breaking down pyruvate nearly 26 times faster than it
could be produced indicating that the extract is relatively enriched for pathways downstream
of pyruvate, in addition to those that deplete glycolytic intermediates. In the YT-M and
the YT-E conditions, the consumption of pyruvate was greater than the DF condition,
however, the potential consumption from downstream pathways was not enough to deplete
the pyruvate reservoirs created by the extract. The YT-E extract, in particular, was able
to maintain a reservoir of pyruvate that nearly matched the total pyruvate that it could
consume within a 24-hour time frame.
3.5 Discussion
The metabolic potential of crude extract preparations and their use for metabolite production
can be assessed through exploration of their proteomic and metabolic profiles. Despite
progress in the use of crude extracts for protein expression, the actual content of a crude
extract and its metabolic potential is poorly understood. We sought to address this deficiency
by exploring the protein profiles of different cell extract preparations and assess their ability
to produce pyruvate from glucose in CFME. As a central player in a variety of cellular
processes, pyruvate is not only a key indicator of a crude extract’s glycolytic potential, but
also an important proxy for the extract’s ability to produce small molecules of commercial
interest [103]. To explore the optimization of precursor production in cell-free extracts, we
modulated cell growth conditions in order to create global changes in an extract’s protein
content. Given the static nature of the protein content in crude extracts, understanding the
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Table 3.2: The percent glucose consumed and the percent glucose converted to pooled
pyruvate were determined after 24 hours of feeding the reactions 250 mM glucose and
measuring the remaining glucose concentration and the amount of pyruvate produced,
respectively. The percent of glucose converted to pyruvate and downstream metabolism
was determined after measuring the consumption rate of 25 mM pyruvate after 24 hours in
the absence of glucose. Conversion amounts were determined using n=3 biological replicates.
Extract % Glu Consumed % of Consumed Glu-
cose Converted to
Pooled Pyruvatea




DF 15.55% 0.92% 24.55%
LB 25.74% 3.50% 12.60%
YT-M 18.52% 4.58% 28.83%
YT-E 61.00% 6.57% 13.45%
a Glucose conversion was calculated by measuring pooled pyruvate after 24 h and
converting to glucose.
b The expected glucose used to make the pyruvate consumed by downstream metabolism
was combined with the glucose consumed in order to produce the pooled pyruvate to
account for the breakdown of pyruvate due to downstream metabolism and show the
extract’s ability to synthesize glucose from pyruvate without the sink of downstream
metabolism.
proteomic and metabolic potential of these systems can provide an effective platform onto
which heterologous pathways could be engineered with predictable effects and high yields.
The ability of each crude extract to potentially break down glucose is evident from
proteomic analyses. All growth conditions resulted in extracts with the presence of at least
a minimal set of the ten enzymes required for converting glucose to pyruvate. Confirmation
of glycolytic activity was supported by metabolite analyses. The different extracts all
converted glucose to pyruvate in the presence of the appropriate cofactors. Further, a nearly
thirty-fold difference in the amount of pooled pyruvate, after 24-hours, is observed when
comparing the different crude extracts; ranging from 21.29 mM in YT-E and 0.73 mM in
DF. These comparisons showcase the importance of growth conditions when preparing an
extract. Proteomic analyses aid in interpreting the effect of these changes. For example,
the differences in methodology to create the YT-E and the YT-M extracts are seemingly
minor, with the YT-E extract being harvested at an earlier point in the growth phase when
compared to YT-M. However, the effects of this change significantly impact the metabolic
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pathways present in the extract. While both the YT-M and the YT-E extracts are able to
break down pyruvate at a similar rate, the production of pooled pyruvate in the YT-M extract
is only 1/5th that of the YT-E extracts. This difference can be attributed to the prevalence
of the glucose-specific PTS system, which may serve as both an entry and exit for glycolysis
and account for both the increased glucose consumption and the increased production of
pyruvate in the YT-E extract. The absence of the HPr protein in the DF condition removes
this alternative glucose consumption pathway despite a relative abundance of the glucose-
specific proteins. Glucose consumption in cell-free systems can be a robust process and has
been shown in previous studies [57]. As confirmed here, 15-60% of added glucose can be
metabolized by crude extract preparations. Biosynthesis and degradation pathways drawing
from central metabolism, such as those for nucleotides, lipids and amino acids, can affect the
flow of carbon to pyruvate in the DF cell extract. Proteome analyses indicated that the DF
cell extract, which was grown on a minimal medium, is enriched in amino acid and nucleotide
biosynthesis pathways that are not prevalent in the other extract preparations (Figure 3.2,
Supplemental Table A-3). These pathways rely upon intermediates from glycolysis for
their carbon backbones and decrease overall flux towards pyruvate. The upregulation of the
glycolytic enzymes combined with the presence of shunting pathways show a clear path by
which the DF extract could produce pyruvate, but not accumulate pyruvate, in the same
fashion as the YT-E extract where the overwhelming amount of of the produced pyruvate
was shunted downstream.
Each tested growth condition resulted in an extract capable of breaking down pyruvate,
which depletes the pool of this metabolite. The different crude extracts were capable of
consuming up to 90% of added pyruvate. After accounting for this consumption, the overall
production rates of pyruvate for the DF, LB, YT-M, and YT-E extracts are 0.82mM l−1,
0.71mM l−1, 1.14mM l−1, and 1.82mM l−1, respectively. None of the consumed pyruvate
appears to be converted back to glucose. As previously noted, the production of pyruvate
from PEP is effectively irreversible [110]. The pyruvate is likely funneled into downstream
metabolic pathways, and analyses of proteomic information provided insights. GSEA reveals
that carbohydrate metabolism, specifically the Krebs cycle was up-regulated in the LB
extract. Conversely, the YT-E and YT-M extracts were relatively depleted in the Krebs
31
cycle as is common for cells in exponential growth [111]. Interestingly, a component of the
pyruvate dehydrogenase complex (2.3.1.12) was upregulated in both the YT-E and YT-M
extracts, potentially indicating the channeling of pyruvate to acetyl-CoA. Rapid growth,
which might be expected under conditions with abundant resources, results in a need for
biomass components, the biosynthesis of which both starts from intermediates in glycolysis,
and heavily deplete the central precursors therein [112]. Extracts derived from rapidly
reproducing cells can result in active biomass accumulation pathways and can result in a
significant drain on both feed metabolites and cofactors in metabolic engineering endeavors.
These pathways likely lead to the increased consumption of pyruvate observed in the YT-E
and YT-M extracts. While sink pathways draw carbon away from central metabolism, their
effect may be mitigated by the prevalence of upstream pathways providing a balancing effect.
The LB extract is upregulated in both anaplerotic pathways and gluconeogenesis (4.1.3.1,
4.1.1.49, 3.1.3.11) and consumed comparatively less pyruvate than the other extracts.
The use of proteomic and biochemical analyses to describe the metabolic capabilities of a
crude extract provides a useful framework for realizing an extract’s potential applications and
optimization. Changes, either genetic or to growth conditions, can be made to further tailor
a crude extract for desired function. Here, it is evident that growth on a minimal medium
results in the expression of many sink pathways for glycolytic intermediates. Moreover, it
appears specific growth rate, which has been previously examined as a key variable in CFPS
extract preparation, plays a role in reducing sinks due to the Krebs cycle, but at the price
of directing flux towards undetermined biomass accumulation pathways [105]. Proteomic
analysis is a robust technique for determining candidates for genetic manipulation and can
guide in vivo protein overexpression or knockdowns in source strains that will affect the flux
of small molecules after extract preparation. Alternative strategies, such as targeted protein
degradation and pull downs, have been described for the removal of deleterious proteins
from crude extracts after cell lysis to avoid negatively impacting cell growth and survival
[113]. Crude extracts made from high-yielding in vivo pyruvate production strains represent
another opportunity to use in vitro synthetic biology to enable metabolic engineering [114,
115]. Some of the highest producing strains are limited in their genetic tractability, but
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omics data can provide strong candidates for modification and minimize the amount of
genetic engineering needed.
3.6 Conclusion
Critically analyzing the central precursors of cell-free systems as well as how the conditions in
which these extracts are grown can impact the metabolic potential of a cell free system due to
changes in the underlying proteomic content. Notably, we demonstrate that simple changes
in cell-free extract preparation can result in profound differences in metabolite pooling.
Further, these changes in extract preparation have the potential to deplete important
precursors that could be used for synthesis of a final product. These different metabolic
characteristics can be interpreted through the combined use proteomics and metabolomics
techniques. These analytical measurements further our understanding of the composition of
cell-free extracts and provide a rich dataset from which to engineer improved solutions for
metabolite production. These tools can guide genetic manipulations and strain optimization
conditions for maximizing the production of pyruvate, as well as other important biosynthetic
precursors. Feasibly, effective development of crude extracts can lead to a general platform
suitable for testing biochemical pathways and for production of useful metabolites.
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4.1 Abstract
Progress in cell-free protein synthesis (CFPS) has spurred resurgent interest in engineering
complex biological metabolism outside of the cell. Unlike purified enzyme systems, crude
cell-free systems can be prepared for a fraction of the cost and contain endogenous cellular
pathways that can be activated for biosynthesis. However, efforts to use crude cell-
free systems as a bioproduction platform have been hampered by the under-described
complexity of the metabolic networks inherent to a crude lysate. A systems cell-free
metabolic engineering (S-CFME) approach incorporates tools such as shotgun proteomics
to comprehensively describe the biochemical networks in crude lysates for subsequence
refinement and augmentation of complex lysate phenotypes for improved yield and titer. Here
a S-CFME approach has been developed and implemented for in vitro phenol biosynthesis
using crude E. coli lysates. Crude cell lysate metabolic activity was focused towards
the limiting precursor tyrosine by optimization of growth conditions guided by shotgun
proteomics. The result is the activation of a 25-step enzymatic reaction cascade involving
at least three endogenous E. coli metabolic pathways including glycolysis, the pentose
phosphate pathway and the shikimate pathway. Additional modification of this system,
through CFPS of feedback intolerant AroG and phenol-tyrosine lyase from Pasteurella
multicloida, improves yield. This effort demonstrates the ability to activate a long, highly
complex pathway in vitro and provides a framework for harnessing the metabolic potential
of diverse organisms for cell-free metabolic engineering. The more than six-fold increase
in phenol yield with limited genetic manipulation demonstrates the benefits of optimizing
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growth media for crude cell-free extract production and illustrates the advantages of a
systems approach to cell-free metabolic engineering.
4.2 Introduction
Crude cellular lysates were essential reagents in the initial exploration of cellular bio-
chemistry. The identity of each amino acid, the mechanisms of the Krebs cycle, and
transcription and translation were discovered through work performed with crude cell lysates
[37, 38, 39]. These discoveries were possible because crude lysates retain many of the
biochemical functions of living cells, outside of the cell. Isolation of these functions through
various lysate preparation methodologies allows for their study and engineering in a cell-like
context. Recently, engineered crude cell lysates have gained new popularity, reborn in the
age of synthetic biology as cell-free systems[116].
Cell-free systems are complex mixtures of enzymes and small molecules, derived from the
controlled lysis of living cells, that are capable of biochemical reaction cascades. Cell-free
systems have several advantages compared to live cellular systems. Upon lysis, many of
the cellular properties associated with life which impede engineering efforts are eliminated.
Without concerns for cell viability, cytotoxic products can be prepared and resources can
be directed away from growth-associated processes to improve yield. The absence of an
outer membrane removes challenges in product recovery, system handling, and supply of
cofactors and reagents. The destruction of endogenous genetic material through sonication,
bead beating, or enzymatic degradation removes transcriptional and translational regulation
within the system. Additionally, lysate fractionation strategies can be used to isolate,
combine or remove specific biochemical functions to create novel pathways [117]. Purification
of entire metabolic pathways from crude lysates has been demonstrated, but scalability
remains a concern for cell-free systems containing purified components [61, 64]. In contrast,
crude cell-free systems, commonly referred to as cell extracts or lysates, scale similarly
to living cells but can achieve higher turnover rates for complex biochemical functions
including protein synthesis [71, 54]. While allosteric interactions are still present, crude
cell-free systems are a predominantly static biochemical snapshot of the moment the cell
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was lysed. Removal of the outer membrane, endogenous genetic material and many of the
related regulatory systems streamlines engineering efforts.
Crude bacterial cell-free systems have been engineered to carry out in vitro transcription
and translation from an exogeneous genetic template. Early systems consumed small
molecules containing high energy phosphates such as phosphoenolpyruvate and creatine
phosphate to regenerate ATP and fuel cell-free protein synthesis (CFPS) [118]. More recently,
crude Escherichia coli CFPS has been improved by the recycling of inorganic phosphate and
the regeneration of ATP by endogenous lysate metabolism to reduce cost and improve yield
[119]. When provided with sugars or glycolytic intermediates, lysates produce ATP from
central carbon metabolism in vitro [57]. The small molecules produced at the terminal end
of in vitro glycolysis serve as launching points for synthesis of secondary metabolites and
form the basis of most cell-free metabolic engineering (CFME) efforts in crude lysates to
date [58, 95, 103].
Despite the reliance upon native lysate metabolism for substrate processing, energy gener-
ation, cofactor cycling, and protein synthesis, endogenous activities are rarely engineered and
optimized in CFME. Though crude cell-free systems are less complex than living cells, they
can still contain thousands of different proteins capable of interacting and producing complex,
sometimes off-target effects [98, 120]. Further, lysate preparation can result in co-isolation of
deleterious enzymes and metabolites, which can complicate downstream engineering efforts.
To address these issues, it is pertinent to interrogate the system holistically rather
than myopically focusing on discrete pathways where underlying, systemic issues may
complicate desired CFME outcomes. As follows, systems metabolic engineering utilizing
”-omics” measurements and computational tools to interrogate and engineer the complexity
of living cells can be important to the success of CFME. By incorporating tools designed
to characterize and model complex biochemical interactions in vivo, the preparation of
crude cell-free systems can be guided to increase product yield by harnessing the intrinsic
metabolic activity of the lysate. This systems cell-free metabolic engineering (S-CFME)
approach will facilitate creation of more efficient cell-free bioproduction platforms. Building
upon recent efforts using shotgun proteomics to describe the malleability of E. coli cell-free
system endogenous metabolism [121], we present a S-CFME approach to direct metabolic
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activity towards defined intermediates to create and enhance the yield of a non-endogenous
metabolite, phenol. By optimizing both strain culture conditions, informed by proteomics
data, as well as in vitro expression of enzyme variants, cell-free phenol production is greatly
improved (Figure 4.1). As increasingly complex pathways are engineered in crude cell-free
systems, this generally applicable systems approach will become essential to unlocking the
untapped potential of endogenous metabolic activity in crude cell-free systems.
4.3 Materials and methods
4.3.1 Strains, plasmid and reagents
All plasmids used in this study were synthesized by Genscript (Piscataway, New Jersey,
USA). Reagents were purchased from Sigma Aldrich (St. Louis, Missouri, USA) unless
otherwise noted. E. coli BL21 Star (DE3) was purchased from New England Biosciences
(Ipswich, Massachusetts, USA).
4.3.2 Cell extract preparation
Cell extracts were prepared from E. coli BL21 Star (DE3) grown at 37 ◦C in variants of
YPTG (16 g L−1 tryptone, 10 g L−1 yeast extract, 5 g L−1 NaCl, 7 g L−1 KH2PO4, 3 g L
−1
K2HPO4, 18 g L
−1 glucose) and EzRich media. EzRich defined rich media kit was supplied
by Teknova and purchased from VWR (Radnor, Pennsylvania, USA). 5x EZ Supplement
Figure 4.1: Graphical Abstract
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without tyrosine, tryptophan and phenylalanine was purchased from BioWorld (Atlanta,
Georgia, USA). Variants of EZRich media and their designations are summarized in Table
1. In brief, for preparation of cell extracts, 50 mL cultures were grown in baffled Erlenmeyer
flasks to an OD600 of ≈0.8 and induced to 1 mM isopropyl-β-d-thiogalactopyranoside. Cells
were harvested at early exponential phase, about 2.5 hours after induction, corresponding
to OD600 of 2.8 and 4.0 for media YTPG and EzRich variants, respectively. Cells were
harvested by centrifugation at 5000x g for 10 min and washed with S30 buffer (2x, 25 mL,
14 mM magnesium acetate, 60 mM potassium glutamate, 1 mM dithiothreitol and 10 mM
Tris-acetate, pH 8.2). Cell pellets were weighed, flash-frozen in liquid nitrogen, and stored
at –80 ◦C. For extract preparation, cells were thawed and resuspended in 0.8 mL of S30
buffer per mg of cell wet weight before lysis with a Branson Ultrasonics Sonifier SFX250
equipped with a microprobe. Cells were lysed with 530 joules per mL of suspension at 50%
tip amplitude in a 0 ◦C water bath. Post-lysis the cell-slurry was centrifuged twice for 10
minutes at 21,100 x g at 4 ◦C, the supernatant was aliquoted, flash-frozen and stored at –80
◦C.
4.3.3 Cell-free reactions
Cell-free reactions for protein synthesis or phenol production were carried out at 30 ◦C in
25 µL volumes with the following components: 40 mM 13C6 glucose, 1.2 mM ATP; 0.85 mM
each of GTP, UTP and CTP; 34 µg mL−1 folinic acid; 67.7 mM creatine phosphate, 3 µg mL−1
creatine kinase, 0.4 mM pyridoxal 5’-phosphate, 2 mM each of the 20 translatable amino
acids, 0.33 mM nicotinamide adenine dinucleotide (NAD), 0.26 mM coenzyme A (CoA), 33
mM PEP, 18 mM magnesium glutamate, 15 mM ammonium glutamate, 195 mM potassium
glutamate, 1.5 mM spermidine, 1 mM putrescine, 57 mM Bis-Tris pH 7, 100 ng µL−1 plasmid
DNA and 15 µL cell extract adjusted to 10 mg mL−1 by Bradford assay. Cell-free reactions
were overlaid with 100 µL of tributyrin to prevent evaporation. Cell-free protein synthesis of
sfGFP was performed in a 96 well plate in a Perkin Elmer EnSpire 2300 for 8 hours, with
fluorescent measurements (excitation 488 nm, emission 509 nm) every 20 minutes. Phenol
production reactions were run for 48 hours in 1.5 mL microcentrifuge tubes. After 48 hours,
phenol production reactions were vortexed and centrifuged for 10 minutes at 21,100 x g at
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4 ◦C. 50 µL of tributyrin overlay was removed, added to 0.5 mL of dicholoromethane and
subjected to analysis by GCMS.
4.3.4 Phenol quantitation
In vitro synthesized phenol was quantified on an Agilent 7890A gas chromatograph equipped
with a 5975C mass spectrometer. Tributyrin overlays diluted with dicholormethane were
injected onto a HP-5MS column at 40 ◦C. Initial oven temperature was held for 3 minutes,
ramped to 120 ◦C at 22 ◦C/min and held for 1 additional minute. The oven was then heated
to 325 ◦C and maintained for 3 minutes. 13C6,
13C4, and non-labeled phenol were monitored
at m/z 100.1, 98.1, and 96.1 respectively. Phenol was quantified by peak integration and
comparison to a standard curve in Thermo Xcalibur. Two technical replicates were measured
for every sample.
4.3.5 Proteomics
To prepare cell lysates for proteomic analysis, each lysate was precipitated with tri-
choloroacetic acid 20% w/v. Precipitated proteins were pelleted by centrifugation at 21000
x g for 10 min at 4 ◦C and washed with acetone (2x, 1 mL, -20 ◦C). Acetone was decanted,
and pellets were air dried. Protein pellets were resolubilized in 8 M urea, 10 mM DTT,
100 mM Tris–HCl, pH 8.0, alkylated with 20 mM iodoacetamide, and digested with trypsin
as previously described [121]. Digestion was halted by addition of 200 mM NaCl and 0.1%
formic acid. Tryptic peptides were then passed through a 10 kDa molecular weight cutoff
size exclusion filter (Microcon YM-10, Millipore, Billerica MA). Peptides were quantified by
BCA assay and 50 µg were loaded via a pressure cell onto the reverse phase (Aqua C18, 5
micron, Phenomenex, Torrance, CA) of a biphasic strong cation exchange (Luna SCX, 5
micron, Phenomenex, Torrance, CA) and C18 column, desalted, and eluted onto the strong
cation phase. Digests were analyzed by two-dimensional liquid chromatography in line with
nanospray tandem MS using an LTQ-Orbitrap XL mass spectrometer (Thermo Scientific).
Peptides were eluted with 4 salt cuts of ammonium acetate (10, 25, 50, and 100 mM),
each followed by a 100-minute organic gradient to separate peptides on C18 [99]. The mass
40
spectrometer was operated in data dependent acquisition (one full scan at 30K resolution
followed by 5 MS/MS scans in the LTQ, 3 m/z isolation window, dynamic exclusion: window
= 1 m/z, duration = 60 s). Using MyriMatch (version 2.1.138), protein identifications
were obtained by matching observed MS/MS spectra to predicted peptide fragmentation
spectra from a database of 4156 Escherichia coli BL21 (DE3) protein sequences (proteome
UP000002032) appended with common contaminants and decoy sequences [69]. Protein
identifications were assembled from filtered peptide spectrum matches (PSM) using IDPicker,
version 3.1.599 (2 peptide minimum per protein; protein false-discovery rate <0.8%; peptide
false-discovery rate < 0.3%, spectrum false-discovery rate < 0.1%) [100]. PSMs were assigned
matched-ion intensities by integration of observed peptide fragment peaks; unique PSMs
matching individual proteins were summed to derive protein intensity. Protein intensities
were log2 transformed, normalized (LOESS) and standardized across all samples by median
absolute deviation using InfernoRDN [122]. To simulate the lower bounds of detection,
intensities of protein not observed in a condition, but described globally were imputed
with a normal distribution (downshift = 1.8, width = 3) using Persues [123]. Enzyme
Commission numbers were assigned by BlastKOALA [101]. Full tables of detected proteins,
tryptic peptides are deposited in Supplemental Table B-1 and Supplemental Table B-
2. Descriptions of these tables and their legends are supplied in Supporting Information.
4.3.6 Statistical analysis
Three biological replicates were used for all proteomics measurements. Differences in protein
abundance, based upon average log2 protein intensity, were determined by Student’s t-test
(2-tailed, unpaired, equal variance). Statistics were performed, and plots were generated in
R (version 3.5.3) with packages Tidyverse and ggpubr [124].
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4.4 Results and Discussion
4.4.1 Enabling phenol production in E. coli cell-free systems
Aromatic compounds are valuable chemicals with uses as industrial solvents, fuels, and
substrates for chemical synthesis. Largely derived from petroleum, manufacturing of
aromatic compounds by microbial fermentation of a low-cost sugar substrate would present
an environmentally friendly alternative. As aromatic rings are present in nucleotide bases
and in three of the proteinogenic amino acids, many organisms have biosynthetic pathways
to produce aromatic compounds. The building blocks for the aromatic amino acids
phenylalanine, tryptophan, and tyrosine result from the shikimate pathway. Additionally, the
shikimate pathway is the metabolic launching point for biosynthesis of phenylpropanoids,
a diverse class of secondary metabolites synthesized from iterative additions of malonyl-
and coumaroyl-CoAs, that include medicinally valuable compounds such as flavonoids and
stilbenoids. Others have succeeded in developing in vitro biosynthetic pathways for highly
conjugated compounds including acyl-CoAs, but production of aromatic compounds by the
shikimate pathway in vitro has not been explored [125].
Phenol is one of the simplest aromatic compounds, consisting of a six-carbon aromatic
ring appended with a single hydroxyl group. Phenol-tyrosine lyases (PTL, 4.1.99.2) from
various enterobacteria have been found to catalyze the synthesis of phenol from the
amino acid tyrosine, and recently, Kim et al. successfully produced microbially derived
phenol by heterologous expression of PTL. Improving substrate availability by engineering
tyrosine biosynthesis increased phenol yield, but cytotoxicity limited productivity [126]. The
reduced impact of highly cytotoxic products on cell-free bioproduction platforms provides
an attractive alternative for phenol biosynthesis [127].
While many microorganisms, including E. coli, can make their own tyrosine, high-yield
tyrosine biosynthesis is a complex phenotype. Tyrosine biosynthesis requires not only the
four and three carbon building blocks, erythrose 4-phosphate (E4P) and phosphoenolpyru-
vate (PEP), which are condensed to form 3-deoxy-D-arabino-heptuloseonate 7-phosphate
(DAHP), but an additional PEP, ATP, and NADPH are also required. NADPH can be
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regenerated through the prephenate dehydrogenase activity of TyrA (5.4.99.5/1.3.1.12),
however PEP and ATP must be generated outside of the shikimate pathway (Figure 4.2).
In this work, the one-pot in vitro biosynthesis of phenol was achieved by coupling
endogenous production of tyrosine from glucose with CFPS of PTL from Pasteurella
multocida. Fully-labeled 13C6 glucose was used as the carbon source to distinguish between
phenol synthesized from amino acids added as a substrate for CFPS and the desired
full pathway. CFPS and phenol production both require exogenous ATP; as oxidative
phosphorylation is not expected to be active in these systems, creatine phosphate and
creatine kinase were added to energize these reactions [128]. Simultaneous addition of PTL
template DNA, labeled glucose, and creatine kinase initiated in vitro phenol production,
which proceeded over the course of 48 hours and was quantified by GC/MS.
4.4.2 Characterization of crude cell-free systems prepared from
defined media
Previously we demonstrated that composition of growth media for cell extract preparation
can alter lysate metabolic activity [121]. Small changes in available nutrients and growth
conditions result in large compensatory shifts in protein abundance which can be observed
with shotgun proteomics. To provide fine control over media conditions, a cell-free system
based upon growth on defined media was developed. Using this system, variables potentially
impacting tyrosine production including carbon source and presence of aromatic compounds
in the media were investigated. In particular, the effect of aromatic amino acids and
nucleotide bases in the media was explored. Impacts of each change to the growth media
were evaluated by shotgun proteomics and used to inform subsequent modifications. All
media compositions are detailed in Table 4.1.
E. coli cell-free systems for protein production are generally grown using the rich, complex
media YTPG, which consists of five components: yeast extract, tryptone, NaCl, potassium
phosphate and glucose. Yeast extract and tryptone contain many different complex
biomolecules with significant batch to batch variations; this presents limited opportunity
for modification and optimization. The rich, defined media described by Neidhardt et
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Figure 4.2: Abbreviated metabolic map of phenol biosynthesis by heterologous
expression of phenol-tyrosine lyase in E. coli. Only enzymatic transformation found
significant in this study are represented. Heterologous enzymes expressed by cell-
free protein synthesis are colored red. Symbols: Full yellow circles, ATP; half
yellow circles, ADP; empty yellow circles, AMP; full purple circles, NADPH; half
purple circles, NADP+; full blue circles, NADH; half blue circles, NAD+. Metabolite
abbreviations: G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; F1,6BP, fructose 1,6-
bisphosphate; G3P, glyceraldehyde-3-phosphate; PEP, phosphoenolpyruvate; R5P, ribose
5-phosphate; X5P, xylulose 5-phosphate; S7P, sedoheptulose 7-phosphate; E4P, erythrose 4-
phosphate; PrPP, phosphoribosyl pyrophosphate; DAHP, 3-deoxy-D-arabinoheptulosonate
7-phosphate; 3DHS, 3-dehydroshikimate; S3P, shikimate 3-phosphate; I3GP, indole-3-
glycerol phosphate. Enzyme abbreviations with Enzyme Commission numbers: G6PDH,
glucose 6-phosphate dehydrogenase (1.1.1.49); AraA, arabinose isomerase (5.3.1.4); PRPPS,
phosphoribosyl pyrophosphate synthase (2.7.6.1); Rpe, ribulose 5-phosphate 3-epimerase
(5.1.3.1); TktA, transketolase 1 (2.2.1.1); FBPase I, fructose 1,6-bisphosphotase class
I (3.1.3.11); FBPase II, fructose 1,6-bisphosphotase class II (3.1.3.11); GlyK, glycerol
kinase (2.7.1.30); GapC, glyceraldehyde-3-phosphoate dehydrogenase (1.2.1.12); PEPCK,
phosphoenolpyruvate carboxykinase (4.1.1.49); PpsA, phosphoenolpyruvate synthase
(2.7.9.2); PykAF, pyruvate kinase (2.7.1.40); AroFGH, deoxy-D-arabinoheptulosonate 7-
phosphate synthase (2.5.1.54); AroD, 3-dehydroquinate dehydratase (4.2.1.10); AroL,
Shikimate kinase II (2.7.1.71); PheA, chorismate mutase/ prephenate dehydratase
(5.4.99.5/4.2.1.51); TyrA, chorismate mutase/prephenate dehydrogenase (5.4.99.5/1.3.1.12);
TrpD, anthranilate phosphoribosyltransferase (2.4.2.18); TrpE, anthranilate synthase
component 1 (4.1.3.27); TrpCF, multifunctional fusion protein (4.1.1.48/5.3.1.24); TrpAB,
tryptophan synthase (4.2.1.20); PTL, phenol-tyrosine lyase from Pasteurella multocida
(4.1.99.2).
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Table 4.1: Composition of each EzRich derived media.
Growth Condition Supplement EZ ACGU mix Carbon Source
EzRich 1x + 11 mM Glucose
EzGlc 1x + 100 mM Glucose
XtraGlc 2.5x + 100 mM Glucose
AAA -Trp, Tyr, Phe + 100 mM Glucose
ACGU 1x - 100 mM Glucose
EzAra 1x + 100 mM Arabinose
EzGly 1x + 100 mM Glycerol
DDGlc -Trp, Tyr, Phe - 100 mM Glucose
al. and commercially available as ”EzRich” by Teknova provides greater flexibility as each
component can be individually changed [129]. A modified CFPS extract preparation protocol
was developed based upon EZRich media.
Maintaining CFPS capabilities was a priority in the development of this system as in vitro
protein expression can shorten design-build-test cycles and allow synthesis of different end
products. Further, as has been demonstrated in the engineering of isoprenoid biosynthesis,
tuning of expression levels of terminal synthases is an important step to optimize product
yield [130]. In development of a crude cell-free system grown from defined media, several
growth variables were modified and CFPS capabilities of the resulting systems were compared
to the standard, YTPG CFPS system. Optimal OD600 at harvest was adjusted to
compensate for a higher terminal OD600 compared to YTPG (Figure 4.7). As EzRich
contains different molar quantities of amino acids and glucose when compared to YTPG,
(Supplemental Table 4.2) several variants of EzRich were assessed to account for different
nutrient concentrations.
CFPS yield of sfGFP from plasmid pJL1 was used to benchmark all cell-free systems
generated for this study. Lower amino acid concentrations did not significantly impact CFPS
capabilities (Figure 4.8). However, increasing the proportion of the Ez Supplement in the
media beyond 1x was deleterious to CFPS yield. With minimal optimization, the EzGlc
media resulted in the most comparable CFPS to YTPG and was thus selected for further
characterization. Further, none of the other variant cell-free systems grown on defined media
exhibited significant differences in vitro protein synthesis yields (Figure 4.9). To assess the
impact of the growth conditions on the proteins involved in CFPS, the 87 proteins in the
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minimal PURE system were identified in all cell-free systems and statistical differences in
their abundances were measured [98]. Across cell-free systems generated for this study, 26
protein elements of the PURE system [44] were identified to be differentially abundant with a
fold change of greater than two compared to YTPG in at least one condition (Figure 4.10).
It remains unclear, which individual proteins have the largest impact on in vitro protein
synthesis yield. However, others suggest that some variation in concentration of ribosome
subunits is permissible [105], which is corroborated by these data.
Cell-free phenol yield was assessed in both YTPG and EzGlc cell-free systems (Figure
4.3). Additionally, the protein content of each system was measured and compared
with a focus on changes within the 25 enzymes directly involved in tyrosine biosynthesis
(Figure 4.3A). Global changes in protein content are represented in Figure 4.3C and in
Supplemental Table B-3. Notably, there was a large increase in nearly all amino acid
biosynthesis pathways when cell-free systems are prepared from EzGlc media compared to
the YTPG extracts. These include tyrosine biosynthesis enzymes DAHP synthase (AroF,
2.5.1.54), 3-dehydroquinate dehydratase (AroD, 4.2.1.10), and TyrA, which were upregulated
by 98-fold, 2.5-fold and 66-fold, respectively. However, despite these large increases in
protein abundance, phenol yield only increased from 10.9 mg L−1 in the YTPG condition
to 12.4 mg L−1 in the EzGlc condition (p=0.048, Figure 4.3B). This comparatively small
increase in yield is likely caused by the addition of new carbon sinks in the form of other
upregulated amino acid biosynthesis pathways.
4.4.3 Impact of carbon source on in vitro phenol biosynthesis
In E. coli, all three aromatic amino acids are derived from chorismate, the nine-carbon
product of the shikimate pathway. Metabolic flux to each amino acid is regulated primarily
by transcriptional control [105]. While endogenous transcription, and the associated
regulation, are not expected to be present in cell-free systems, tyrosine biosynthesis is also
limited by the availability of shikimate pathway precursors PEP and E4P derived from
glycolysis and the pentose phosphate pathway, respectively [131].
With the goal of increasing precursor supply, two media with alternative carbon
sources were prepared. The EzAra media contains the pentose sugar arabinose, which
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Figure 4.3: A) Comparison of protein abundance in tyrosine metabolism (including
abbreviated glycolysis, pentose phosphate pathway, and shikimate pathway) between
complex media YTPG and defined media EzGlc. Each bar represents the mean log2(fold
change) in protein abundance in a variant growth media compared to mean protein
abundance in the YTPG cell-free system. Significance was determined by a two-tailed
Student’s t-test compared to the YTPG cell-free system:*, p<0.05. Pathway enzymes not
depicted can be assumed to have undergone no significant change in abundance. B) in
vitro phenol biosynthesis from 13C6 glucose in a one-pot CFPS-ME reaction measured at 48
hours. Only 13C6 phenol is depicted (m/z=100.1). Values represent averages of technical
replicates (n=3) and errors bars represent 1 SD. Significance was determined by a two-
tailed Student’s t-test compared to the YTPG cell-free system:*, p<0.05; ns, p≥0.05. C)
Volcano plot of proteomic data. Volcano plots are depicted with the log2(fold change) in
abundance of each protein and the -log10(p-value) derived from performing a Student’s
T-test. The average abundance of each protein in the EzGlc cell-free system (n=3) was
compared against the average abundance of each protein in the YTPG cell-free system
(n=3). Red points show proteins which have been significantly up or down regulated at
least twofold and p<0.01. Black points are not significantly changed. Significantly changed
proteins are listed in Supplemental Table B-3.
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was hypothesized to upregulate transketolase and transaldolase as arabinose enters E. coli
metabolism through the pentose phosphate pathway. Media EzGly contains glycerol which is
converted into the glycolytic intermediate 3-phosphoglycerate and was added to upregulate
gluconeogenesis and stabilize the pool of PEP.
Changing carbon sources resulted in large increases in several proteins (Figure 4.4).
Glycerol kinase (GlyK, 2.7.1.30) was upregulated 128-fold in the EzGly condition and
arabinose isomerase (AraA, 5.3.1.4) was upregulated by three orders of magnitude in
the EzAra condition. Changes within central carbon metabolism were less dramatic,
but nonetheless significant. Downregulation of glyceraldehyde-3-phosphate dehydrogenase
(GapC, 1.2.1.12) and upregulation of both fructose 1,6, bisphosphatase I and II (FBPase
I and II, 3.1.3.11) were observed in the EzGly conditions and may result in an increased
gluconeogenic potential. Further, both phosphoenolpyruvate carboxykinase (PEPCK,
4.1.1.49) and phosphoenolpyruvate synthase (PpsA, 2.7.9.2) were upregulated by growth on
EzGly (Figure 4.4A). This suggests that growth on a triose has the potential to stabilize the
pool of PEP in a cell lysate. The EzAra growth media did not result in any other substantial
changes within tyrosine biosynthesis; global changes in protein content are summarized in
Supplemental Table B-4.
Unfortunately, growth on media EzAra and EzGly resulted in decreasing two DAHP
synthase isozymes (AroHF, 2.5.1.54), which would limit tyrosine production. Further, both
conditions reduced abundance of TyrA, which in vivo engineering efforts have shown is
critical to tyrosine production [132]. Although both conditions also downregulated the
competing bifunctional phenylalanine biosynthesis enzyme PheA (5.4.99.5/4.1.1.51), it does
not appear as though this compensated for the deleterious changes. The EzAra and EzGly
cell-free systems both underperformed the EzGlc and base YTPG cell-free systems producing
8.8 mg L−1 and 5.8 mg L−1 phenol, respectively (Figure 4.4B). Due to their reduced phenol
yield and the downregulation of key enzymes, both the EzAra and EzGly media were not
studied further.
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Figure 4.4: A) Comparison of protein abundance in tyrosine metabolism (including
abbreviated glycolysis, pentose phosphate pathway, shikimate pathway, arabinose uptake
and glycerol uptake) between EzGlc and media with variant carbon source EzAra and EzGly.
Each bar represents the mean log2(fold change) in protein abundance in a variant growth
media compared to mean protein abundance in the EzGlc cell-free system. Significance was
determined by a two-tailed Student’s t-test compared to the EzGlc cell-free system:*, p<0.05.
Pathway enzymes not depicted can be assumed to have undergone no significant change in
abundance. B) in vitro phenol biosynthesis from 13C6 glucose in a one-pot CFPS-ME reaction
measured at 48 hours. Only 13C6 phenol is depicted (m/z=100.1). Values represent averages
of technical replicates (n=3) and errors bars represent 1 SD. Significance was determined by
a two-tailed Student’s t-test compared to the EzGlc cell-free system:*, p<0.05; ns, p≥0.05.
C) Volcano plot of proteomic data. Volcano plots are depicted with the log2(fold change)
in abundance of each protein and the -log10(p-value) derived from performing a Student’s
T-test. The average abundance of each protein in the EzGlc cell-free system (n=3) was
compared against the average abundance of each protein in the EzAra (n=3) and EzGly
(n=3) cell-free system. Red points show proteins which have been significantly up or
down regulated at least twofold and p<0.01. Black points are not significantly changed.
Significantly changed proteins are listed in Supplemental Table B-4.
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4.4.4 Removing media components during growth activates biosyn-
thetic pathways in cell lysates
Our prior work showed that abundances of glycolytic enzymes were relatively unchanged
across several growth conditions [121]. However, larger shifts in protein abundance were
observed outside of central carbon metabolism. With the goal of increasing the activity of
aromatic compound biosynthesis in vitro, several dropout media were created. Media AAA
is a tyrosine, tryptophan and phenylalanine dropout that was hypothesized to increase flux
towards the aromatic amino acids. Media ACGU is a dropout of the EzRich nucleotide
mixture. As nucleotides are synthesized from ribose-5-phosphate, this dropout was expected
to increase flux to the pentose phosphate pathway and increase yield of aromatic compounds
in vitro.
Media AAA performed as predicted with upregulation of rate-limiting DAHP synthases
AroH and AroF as well as tyrosine-forming dehydrogenase TyrA. However, 3-dehydroquinate
synthetase (AroD, 4.2.3.4) was downregulated by nearly two-fold and enzymes known to
impact E4P supply were not affected (Figure 4.5A). The impact of media ACGU was less
predictable. An absence of nucleotides reduced the abundance of both oxidative pentose
phosphate pathway enzyme glucose-6-phosphate dehydrogenase (G6PDH, 1.1.1.49) and
transketolase (TktA, 2.2.1.1). Intriguingly, growth on media ACGU upregulated shikimate
kinase 2 (AroL, 2.7.1.71) four-fold. This effect may be elicited by the increased demand
for tetrahydrofolic acid, a chorismate derivative and an essential cofactor in nucleic acid
biosynthesis.
Though decreases in AroD in the AAA condition were observed, the increases in rate-
limiting enzymes resulted in a 41.5% increase in phenol yield to 16.4 mg L−1 (Figure 4.5B).
Further, cell extracts prepared without nucleotides synthesized phenol at amounts similar
to EzGlc despite downregulation of the pentose phosphate pathway. Through evaluation
of individual changes to growth media composition by both their impact on phenol yield
and the changes they elicit in the lysate proteome, new composite growth conditions can be
designed to target specific metabolic pathways.
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Figure 4.5: A) Comparison of protein abundance in tyrosine metabolism (including
abbreviated glycolysis, pentose phosphate pathway, shikimate pathway, and aromatic amino
acid biosynthesis) between EzGlc and defined media with aromatic compound dropouts
AAA, ACGU and GlcDD. Each bar represents the mean log2(fold change) in protein
abundance in a variant growth media compared to mean protein abundance in the EzGlc
cell-free system. Significance was determined by a two-tailed Student’s t-test compared to
the EzGlc cell-free system:*, p<0.05. Pathway enzymes not depicted can be assumed to
have undergone no significant change in abundance. B) in vitro phenol biosynthesis from
13C6 glucose in a one-pot CFPS-ME reaction measured at 48 hours. Only
13C6 phenol is
depicted (m/z=100.1). Values represent averages of technical replicates (n=3) and errors
bars represent 1 SD. Significance was determined by a two-tailed Student’s t-test compared
to the EzGlc cell-free system:*, p<0.05; ns, p≥0.05. C) Volcano plot of proteomic data.
Volcano plots are depicted with the log2(fold change) in abundance of each protein and the
-log10(p-value) derived from performing a Student’s T-test. The average abundance of each
protein in the EzGlc cell-free system (n=3) was compared against the average abundance
of each protein in the AAA (n=3), ACGU (n=3), and GlcDD (n=3) cell-free system. Red
points show proteins which have been significantly up or down regulated at least twofold
and p<0.01. Black points are not significantly changed. Significantly changed proteins are
listed in Supplemental Table B-5.
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While the AAA media was the only one able to increase in vitro phenol yield, the ACGU
media upregulated unexpected enzymes within the shikimate pathway, which provoked
further investigation. A media dropping out both aromatic amino acids and nucleotides with
glucose as the carbon source was explored to combine the positive effects of these two sets
of changes to the growth media composition. This media, dubbed double dropout glucose
(DDGlc), was used to prepare a cell-free system and characterized as previously described.
This new system further improved phenol biosynthesis to 25.8 mg L−1 and contained several
uniquely upregulated enzymes (Figure 4.5C, Supplemental Table B-5).
The DDGlc media shares many of the upregulated proteins of its parent cell-free systems,
AAA and ACGU. TyrA, AroH and AroL are all upregulated compared to the EzGlc cell-
free system. While 3-dehydroquinate synthase is still downregulated in the GlcDD cell-free
system, the downregulation of transketolase in the ACGU condition is not maintained in the
double dropout. As there are many potential sinks of PEP, determination of the metabolic
fate of PEP in the various cell-free systems will likely be necessary to further increase phenol
yield.
The double dropout media results in the unique downregulation of ribulose 5-phopshate
epimerase (Rpe, 5.1.3.1), which was not observed in any of the parent conditions. This
change has the potential to impact E4P supply by limiting the amount of glucose which
enters the pentose phosphate pathway in vitro. Further, the DDGlc media upregulates
anthranilate PrPP transferase (TrpD, 2.4.2.18), a key enzyme in tryptophan biosynthesis
which utilizes resources from both the shikimate and pentose phosphate pathway. It is
possible that the observed increased flux to tyrosine is a consequence of a greater increase
in flux to tryptophan. Eliminating the conversion of chorismate to anthranilate would help
channel shikimate pathway products towards tyrosine.
4.4.5 CFPS of rate-limiting enzyme, AroG
Post-lysis addition of enzymes by cell-free protein synthesis not only enables synthesis of
heterologous products but can also alter endogenous metabolism. Expression of additional
copies of endogenous rate-limiting enzymes can improve flux towards specific pathways [133].
However, expression of multiple constructs in a single cell-free can reduce in vitro protein
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yield. In this work, tyrosine availability was assumed to limit phenol production as PTL
activity is not expected to be limiting below tyrosine concentrations approaching 1 mM
[134]. When only PTL was expressed by CFPS in each cell-free system, unlabeled phenol
production was relatively unchanged (Figure S5). This supports the assertation that the
metabolic bottleneck lies upstream of the phenol-tyrosine lyase step. However when sfGFP
was expressed by CFPS, in addition to PTL, both fully-labelled and unlabeled phenol yield
decreased.
In addition to synthesizing additional copies of endogenous enzymes, mutants can be
expressed to overcome allosteric feedback regulation. Three isozymes of DAHP synthase,
AroGHF, carry out the rate-limiting condensation of E4P and PEP in aromatic amino acid
biosynthesis; each isozyme is allosterically inhibited by one of the aromatic amino acids.
AroG, which is sensitive to feedback inhibition by phenylalanine and makes up 80% of
endogenous DAHP synthase activity, was expressed along with PTL in the DDGlc cell-free
system. Because the feedback regulation on AroG is allosteric, overexpression alone did not
increase phenol yield (Figure 4.6). However, a single amino acid mutation (146D→N) in
AroG abolishes feedback inhibition [135]. CFPS of this feedback insensitive mutant along
with PTL resulted in an improved phenol yield of 67.1 mg L−1; this is a more than two-fold
increase compared to DDGlc and a more than six-fold increase compared with the initial
YTPG cell-free system. While simultaneous expression of feedback-insensitive AroG and
PTL resulted in the greatest phenol yield, further optimization of CFPS yield, particularly
from multiple templates, could enable further increases in productivity.
4.5 Conclusion
Crude cell-free systems offer the prospect of building and testing unique combination of
cellular machinery that are freed from the constraints of cellular survival. Optimization
of crude cell lysates for cell-free protein synthesis over the past 30 years has been highly
successful and has increased protein yield by 25,000-fold [136]. While it remains to be seen
what role cell-free systems will play in the growing bioeconomy; their unique features suggest
their largest impact may be in the fields of personalized medicine and remote bioproduction
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Figure 4.6: In vitro phenol biosynthesis from 13C6 glucose in a one-pot CFPS-ME reaction
in GlcDD cell-free system measured at 48 hours. PTL (4.1.99.2) from P. multocida, sfGFP,
AroG (2.5.1.54) and feedback-insensitive AroG are expressed by CFPS at the provided
concentrations. Only 13C6 phenol is depicted (m/z=100.1). Values represent averages of
technical replicates (n=3) and errors bars represent 1 SD. Significance was determined by
a two-tailed Student’s t-test compared to the GlcDD-PTL 10 ng µL−1 cell-free reaction:*,
p<0.05; ns, p≥0.05.
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[137]. To reach this goal, the characterization of the metabolic and biochemical activities of
crude cell-free systems will be paramount, especially for benchmarking complex biochemical
processes like protein synthesis. This work demonstrates the potential of coupling systems-
wide omics measurements to inform the engineering and design of unique biological pathways
that capitalize on the underlying metabolic potential of a crude cell-free system. The
proteome-wide impact of small changes to lysate preparation, which resulted in a more
than six-fold increase in in vitro phenol biosynthesis, underscores the importance of global
analytical measurements, such as untargeted proteomics, to understanding these complex,
cell-like systems. Furthermore, as the demand for commercial-scale, low variability, quality-
controlled cell-free systems grows, measures of lysate content and activity that are more
descriptive than total protein concentration will be required [138]. Nevertheless, cell-free
platforms have greater flexibility and are easier to manipulate relative to cellular platforms.
With the application of burgeoning systems metabolic engineering tools, including rapid
metabolomics and predictions of metabolic fluxes, bioproduction in crude cell-free systems
can achieve similar improvements as those seen with protein synthesis and compete with
living cell platforms [139, 140].
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4.7 Appendix
Figure 4.7: Growth profile of E. coli BL21De3(star) grown on preliminary cell-free system
preparation media. All samples were induced to 1 mM IPTG at OD 0.6. Symbols: circles,
YTPG; triangles, EzRich; squares, EzGlc; diamonds, XtrRich.
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Figure 4.8: CFPS of sfGFP in cell-free systems from preliminary growth media measured
at t=8 hours. Glucose (40 mM), creatine kinase (2.5 U/mL) and creatine phosphate (67.7
mM) were provided to energize the reaction. Values represent averages of technical replicates
(at least n=2). Significance was determined by a two-tailed Student’s t-test compared to
the YTPG cell-free system:*, p<0.05; ns, p≥0.05.
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Figure 4.9: CFPS of sfGFP in cell-free systems from YTPG and EzRich variant growth
media measured at t=8 hours. Glucose (40 mM), creatine kinase (2.5 U/mL) and creatine
phosphate (67.7 mM) were provided to energize the reaction. Values represent averages of
technical replicates (at least n=2). Significance was determined by a two-tailed Student’s
t-test compared to the YTPG cell-free system:*, p<0.05; ns, p≥0.05.
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Figure 4.10: Comparison of protein abundance in transcriptional and translation machinery
across variant growth conditions. Each bar represents the mean log2(fold change) in protein
abundance in a variant growth media compared to mean protein abundance in the YTPG
cell-free system. Significance was determined by a two-tailed Student’s t-test compared to
the YTPG cell-free system:*, p<0.05.
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Figure 4.11: In vitro phenol biosynthesis from 13C6 glucose in a one-pot CFPS-ME reaction
in EzGlc, each of the variant growth media cell-free systems, and GlcDD with variant CPFS
reactions were measured at 48 hours. PTL from P. multocida is expressed by CFPS. Bar
chart coloration depicts 13C0,
13C4, and
13C6 phenol is depicted (m/z=94.1, 98.1, 100.1).
Values represent averages of technical replicates (n=3).
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Table 4.2: Amino acid Composition of each EzRich derived media.












Ala 9.76 0.80 0.08 2.00 0.21
Arg 4.65 5.20 1.12 13.00 2.80
Asp 12.35 0.40 0.03 1.00 0.08
Cys 1.02 0.10 0.10 0.25 0.24
Glu 27.81 0.60 0.02 1.50 0.05
Gly 7.15 0.80 0.11 2.00 0.28
His 3.07 0.20 0.07 0.50 0.16
Ile 7.45 0.40 0.05 1.00 0.13
Leu 12.37 0.80 0.06 2.00 0.16
Lys 10.00 0.40 0.04 1.00 0.10
Met 3.06 0.20 0.07 0.50 0.16
Phe 5.47 0.40 0.07 1.00 0.18
Pro 13.97 0.40 0.03 1.00 0.07
Ser 10.30 10.00 0.97 25.00 2.43
Thr 7.43 0.40 0.05 1.00 0.13
Trp 1.21 0.10 0.08 0.25 0.21
Tyr 2.08 0.20 0.10 0.50 0.24
Val 10.17 0.60 0.06 1.50 0.15
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Chapter 5
Describing the chemical diversity of
lasso peptides in the root microbiome
of Populus deltoides with cell-free
peptide synthesis and untargeted
peptidomics
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A version of this chapter by Benjamin P. Mohr, Patricia M. Blair St. Vincent, Richard
J. Giannone, Dale A. Pelletier, Robert L. Hettich, and Mitchel J. Doktycz is submitted to
Microbial Biotechnology
PMBSV carried out initial discovery of lasso peptide BCGs and performed MALDI
experiments. BPM performed bioinformatics and cell-free protein synthesis experiments.
BPM and RJG performed mass spectroscopy. BPM analyzed mass spectroscopy data with
assistance from RJG and RLH. BPM and MJD wrote the article with assistance from
DAP,PMBSV, and RJG.
5.1 Abstract
The interactions with and within the microbiomes of plant roots can promote desirable host
traits including drought tolerance, disease resistance and increased biomass yield. These
interactions can be mediated by natural products expressed by the host plant and the
microbes that populate its rhizosphere. Engineering the production of natural products
from the plant root microbiome to enhance crop productivity and robustness would be
a great boon to agriculture. However, connecting molecules to specific functions is often
limited by both microbial culturability as well as identification of silent biosynthetic gene
clusters encoding small but functional polypeptides that can exhibit non-canonical secondary
structures. Here we develop a high-throughput workflow incorporating bioinformatics, cell-
free protein synthesis, and untargeted peptidomics for the rapid characterization of lasso
peptides – unique cyclical natural products formed by the post-translational processing
of ribosomally synthesized peptides by clusters of tailoring enzymes present within the
root microbiome of Populus deltiodes. Eighty putative lasso peptide gene clusters were
identified; cluster diversity was driven by both precursor peptide sequence and presence of
putative tailoring enzymes identified within the genetic neighborhood encoding the minimal
biosynthetic machinery. Cell-free protein and precursor peptide synthesis was investigated
as a tool for combinatorial expression and characterization of lasso peptide biosynthetic
enzymes, including a novel sulfotransferase identified in twelve Paenibacillaceae. Assessment
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of cell-free production through untargeted peptidomics revealed that identification of lasso
peptides and their modifications was limited by in vitro peptide synthesis fidelity. In vitro
expression enables the high-throughput discovery of natural product structural and chemical
diversity from genome sequences; however, cell-free synthesis of short peptides and their
characterization by associated analytic methods remains challenging, but is necessary to
further the in vitro characterization of these ribosomally synthesized and post-translationally
modified peptide natural products
5.2 Introduction
The plant root microbiome is flush with natural products (NPs) excreted by both fungal
and bacterial members to influence their environment and the community around them.
The structure and function of some of these compounds, such as indoles, are well described,
but a larger number are less understood [141] al., 2016). Automated genome sequence
annotation, based on homology modeling or sequence similarity, has been used to predict
the molecules that members of a microbiome could produce [142]). This is a robust
method for identifying well-described pathways in new organisms, but the functions of many
predicted open reading frames (ORFs) remain unknown [143]. Structural prediction of NPs
is particularly challenging for classes that have few described members or harbor uncommon
modifications, including ribosomally synthesized and post translationally modified peptides
(RiPPs) [2]).
RiPPs are DNA-templated NPs. To form an active product, a ribosomally produced
precursor peptide is sequentially modified by various enzymes. Canonically, modification
of a C-terminal core region is guided by the N-terminal leader peptide, which is cleaved
upon maturation [144, 145]. This separation between recognition sequence and modification
site allows for enzyme promiscuity, but also complicates prediction of product structure.
Fortunately, development of new genome mining tools which use biosynthetic gene cluster
(BGC) architecture to identify regions of interest have allowed identification of numerous
RiPP BGCs [146, 147].
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Lasso peptides constitute a rapidly growing subclass of RiPPs, that have numerous newly
discovered but BGCs [148].The interaction of three protein domains thread the C-terminal
tail of the precursor peptide through an internal macrolactam ring, forming the lasso-like
structure which gives the subclass its name (Figure 5.1). These three functional domains are
split across two to three proteins including a recognition element, called the RiPP recognition
element (RRE) or E; a transglutaminase, called B; and a cyclase, called C [149].
The unique three-dimensional structure of this peptide makes it an attractive scaffold for
bioengineering efforts; to this end, several lasso peptides have been isolated and structurally
characterized with mass spectrometry (MS) and NMR [150, 151, 152]; however functional
characterization remains elusive. Several lasso peptides have antimicrobial or antiviral
properties, but most have no described activity and their natural function remains unknown
[153, 154, 155]. As new lasso peptides are discovered, additional peptide modifications
have been observed beyond the lariat knot. These modifications include acetylation,
phosphorylation, citrulenation, methylation and glycosylation; most of these modifications
are performed by enzymes within the lasso peptide BGC, but some are distally encoded
[156, 157, 145]. Additional as-yet uncharacterized ORFs have also been observed within the
gene neighborhood of many lasso peptides [147]. The cryptic nature of these additional
modifications may contribute to both the lack of understanding regarding the natural
function of lasso peptides as well as their sub-par identification by contemporary analytical
methods.
Figure 5.1: A. General structure of biosynthetic gene clusters for lasso peptides. B. Cartoon
of the expected structure the mature lasso peptide from PDC88. The predicted macrolactam
ring is colored orange and the tail is colored blue.
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The development of a workflow to characterize the sequence, structure and modifications
of lasso peptides would support genome mining efforts and further elucidation of their natural
function. Lasso peptides are commonly isolated from cultured natural producers or expressed
in a heterologous host [158], but both methods suffer from lengthy purification processes
and time-consuming cell culture or genetic engineering steps. Conversely, coupling cell-free
protein synthesis (CFPS) of lasso peptide precursors, maturation enzymes and putative
tailoring enzymes with mass spectroscopy would enable rapid determination of peptide
structure and chemical modification. This method would also facilitate quick production and
validation of variant precursor peptides, which is particularly of interest for interrogation of
the substrate specificity of maturation and tailoring enzymes.
Towards the characterization of the NP diversity of the root microbiome of Populus
deltoides, genomes of 407 root bacterial isolates were mined for the presence of lasso peptide
BGCs. The resulting clusters were grouped based upon sequence similarity and BGC
architecture. Enzyme and peptide sequence motifs were identified and used to predict
the activity and specificity of lasso peptide modifying enzymes, including a novel putative
sulfotransferase. CFPS was investigated as a tool for characterization of peptide NP diversity
within this collection. Untargeted peptide sequencing by LC MS/MS was explored as a
method to confirm peptide production and modification [98].
5.3 Materials and methods
5.3.1 Identification of lasso peptide gene clusters.
Genomes were downloaded from the Joint Genome Institute Integrated Microbial Genomes
and Microbiomes database (IMG, https://img.jgi.doe.gov/) in FASTA format (November
2018) and were submitted for analysis using antiSMASH 3.0 [142]. Lasso peptide BGCs
were identified by analyzing each genome for the presence of an asparagine synthase (Pfam
00733). The asparagine synthase proteins were identified as lasso cyclase proteins if the
gene neighborhood contained a transglutaminase (Pfam 13471). Sequence alignments
and neighbor joining trees were generated from protein FASTA files with R (version
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3.5.3) packages ape, phangorn and seqinR and visualized in iTOL (http://itol.embl.de/)
[159, 160, 161, 162]. Neighbor joining trees were resampled 100 times and branch lengths
with bootstrap supports less than 50 were set to 0.
5.3.2 Co-occurrence analysis.
Gene neighborhoods were analyzed in IMG. Co-occurrence based on protein families was
tabulated for genes +/- 10 ORFs from the lasso cyclase (Pfam 00733). Protein families
were identified as follows: PEP carboxykinase, SSF53795; NTP transf 5, Pfam 14907,
sulfotransfer 3, Pfam 13469. Frequency of occurrence was calculated for each protein family
by dividing the number of counts in the collection by the total number of BGCs.
5.3.3 Matrix-assisted laser ion desorption/ionization time-of-flight
mass spectrometry (MALDI-TOF-MS) analysis.
Cells were grown to stationary phase in Luria Broth or R2A media [163] and small molecules
were extracted with methanol. Extracts were prepared for MALDI-TOF-MS by drying
aliquots and resuspending in 50% acetonitrile. Samples were co-spotted on a MALDI-TOF-
MS stainless steel target plate with saturated α-cyano-4-hydroxycinnamic acid in 75% (v/v)
acetonitrile, 0.1% formic acid. Spectra were acquired on a Bruker Autoflex Speed II equipped
with flexControl software (Bruker Daltonics) in positive ion reflector mode with a mass range
of 800-6000 Da. Data were analyzed in flexAnalysis (Bruker Daltonics).
5.3.4 Sequence similarity networks (SSNs).
EFI-EST (http://efi.igb.illinois.edu/efi-est/) [164] was used to generate SSNs for lasso
peptide precursors and transferases, which were visualized with Cytoscape v. 3.5.1 [165]. E-
value for all-by-all BLAST was 5 for transferases and 10 for precursor peptides. Edge lengths
are proportional to shared sequence identity. Nodes were colored based on phylogeny.
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5.3.5 MEME suite motif identification.
MEME version 5.0.5 (http://meme-suite.org/tools/meme) [166] was run in default mode
from protein FASTA files, identifying 3 motifs for both precursor peptides and transferases.
E-values, representing the product of all p-values for identified motifs on each transferase
protein sequence and p-values for each motif in the precursor peptides are listed in
Supplemental Table C-2 and Supplemental Table C-3, respectively.
5.3.6 Cloning.
PDC88 genes B, C, RRE and the putative sulfotranferase were codon-optimized and
synthesized by Integrated DNA Technologies (IDT, Coralville, IA). Pjl1 was amplified with
primers Pjl1 gib fwd and Pjl1 gib rev. Genes were assembled into Pjl1 with Gibson assembly
master mix (NEB) according to protocol and transformed into TOP10 competent E. coli
(Thermo Fischer). Plasmid was isolated from overnight culture with a Qiagen mini-prep kit
according to protocol.
5.3.7 Cell-free protein synthesis.
Protein synthesis in the PURE systems (New England Biolabs, Ipswich, Massachusetts,
USA) was carried out from PCR products at 37 ◦C for 2 hours with 250 ng template
DNA per 25 µL reaction. Microcin J25 and klebsidin clusters were amplified with primers
PURE T7 fwd and PURE T11 rev, PDC88 cluster was amplified with PURE T7 fwd and
PURE pjl1 rev. E. coli S30 lysate was prepared as described previously [98]. CFPS
from S30 lysate was carried out with plasmid DNA at 37 ◦C for 2 h with 150 ng DNA
per 15 µL reaction. Synthesis of microcin J25 and klebsidin was carried out in one-pot
reactions. PDC88 cluster enzymes were expressed individually, 5 mM 3’-phosphoadenosine-
5’-phosphosulfate was added to reactions containing a sulfotransferase, and then combined
with 10 ng of synthetic PDC88 A1 peptide (Genscript, Piscataway, New Jersey, USA) and
reacted at 37 ◦C for an additional h. CFPS reactions were cleaned-up with a 10 kDa
molecular weight cutoff size exclusion filter (Microcon YM-10, Millipore, Billerica MA) or a
C18 desalting spin column (Thermo Scientific, Waltham, Massachusetts, USA), the solvent
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was then evaporated to dryness and peptides were resuspended in 10 µL of solvent A (5%
(v/v) acetonitrile, 0.1% formic acid) for subsequent analysis.
5.3.8 Untargeted peptide measurements.
Reactions were analyzed by reverse-phase (RP) liquid chromatography in line with nanospray
tandem mass spectrometry (MS/MS) using an Q Exactive Orbitrap Plus MS (Thermo
Scientific, Waltham, Massachusetts, USA). 2 µL of each peptide sample was directly loaded to
a RP column packed with 5 cm of C18 resin (5 micron Kinetex C18, Phenomenex, Torrance,
CA) over 30 minutes as previously detailed [167]. Bound and washed peptides were then
separated by an organic gradient to 50% solvent B (70% (v/v) acetonitrile, 0.1% formic
acid) over 105 minutes on an in-house pulled nanospray emitted pack with 30 cm of Kinetex
C18 resin flowing at 300 nL/min. The MS was operated in positive ion mode with data-
dependent acquisition (one full scan at 70K resolution followed by 5 MS2 scans, 1.8 m/z
isolation window, 0.3 m/z isolation offset, normalized collision energy of 27, unassigned
charged states and charge states 1, 7 and 8 were excluded from analysis). Extracted ion
chromatograms (XICs) were generated from MS1 spectra with Xcalibur (ThermoScientific).
5.3.9 Database dependent peptide identification.
MyriMatch (version 2.1.138, nonspecific digestion, unlimited missed cleavage sites, dynamic
modifications - methionine + 15.9949 Da, tyrosine + 79.9568 Da) was employed to obtain
peptide identifications by matching observed MS/MS spectra to predicted spectra from
a database of either 4156 Escherichia coli BL21 (DE3) protein sequences (proteome
UP000002032) or the 99 protein components of the PURE system appended with the
heterologous protein sequences, common contaminants and decoy sequences [69]. Peptide
spectrum matches (PSMs) were filtered and assigned to proteins using IDPicker, version
3.1.599 (PSM maximum false discover rate 5%) [100]. Identified peptide sequences were
exported and processed in R (version 3.5.3).
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5.3.10 De novo peptide sequencing.
PEAKSX (Bioinformation Solutions Inc, Ontario, Canada) was used to perform de novo
peptide sequencing on each LC MS/MS run. Unassigned high confidence de novo peptides
were assigned potential post-translation modifications with PEAKS PTM.
5.4 Results and Discussion
5.4.1 Analysis of lasso peptide gene cluster architecture within
the Populus root microbiome.
Previously, 339 bacterial isolates from the Populus rhizosphere and endosphere were
sequenced and annotated with the Integrated Microbial Genomes (IMG) pipeline and mined
for BGCs using antiSMASH 3.0 [168, 169]. An additional sixty-eight newly sequenced isolates
have been added to this collection and searched as described previously (Supplemental
Table C-1). AntiSMASH identified eighty-four (84) lasso peptide cyclases from sixty-
three (63) unique organisms. Clusters were selected that met the minimal requirements
to synthesize a lasso peptide; specifically, the lasso cyclase gene neighborhood must contain
a transglutaminase domain (B), a protein with a PQQ domain (E) and at least one potential
lasso precursor peptide. In some cases, the transglutaminase and RRE are fused, but in
many cases, such as in Streptomyces, the RRE is a separate ORF [147]. Eighty (80) intact
lasso peptide BGCs were identified and a phylogenetic tree of the 80 cyclases from these
clusters was constructed (Figure 5.2). The lasso peptide BGCs are distributed among 3
clades: clade 1 consists of cyclases from Actinobacteria, clade 2 consists of cyclases from
α- and γ-Proteobacteria, and clade 3 includes cyclases from α-Proteobacteria, Bacteriodetes
and Firmicutes. Lasso peptides have been isolated from β-Proteobacteria [151]; however, no
lasso cyclases were detected in the sequenced β-Proteobacteria in this collection
Of the lasso peptide BGCs identified, most fall within the diversity outlined by Tietz et
al. [147]. Precursor peptide sequences ranged in length from 13-32 aa, with an average of
21(±4) aa. While the dataset of sequenced organisms is biased for Proteobacteria based on
the prevalence of organisms within the the Populus rhizosphere and thus within the sequenced
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Figure 5.2: Neighbor joining tree of 80 lasso cyclases. Branches are color coded according
to class. Tailoring enzymes found in the gene neighborhood of each lasso cyclase are mapped
following the node name as follows: kinase, SSF53795, circle; nucleotidyltransferase, pfam
14907, square; sulfotransferase, pfam 13469, star; isopetidase, COG1506 , triangle.
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organism collection (Supplemental Figure 5.8). Streptomyces make up only 3.9% of the
isolates and harbor a disproportionate number (69%) of lasso peptide BGCs [168]. Given the
large number of BGCs within the genomes of these organisms and the historical precedence
for discovering complex NPs from Streptomyces, this result is not surprising (Newman and
Cragg, 2016). Clade 1 is made up of the lasso peptides from Streptomyces species, many
of which are predicted to contain disulfide bonds. As previously hypothesized, class I and
III lasso peptides occurr extensively in Actinobacteria (Table 5.1) [158]. Interestingly, a
peptide in clade 3 from Bacillus sp. YR335 is predicted to contain a disulfide bond as well.
Table 5.1
In phyla other than Actinobacteria, lasso peptide diversity is generated through tailoring
enzymes; conserved enzymes present in the gene neighborhood of the minimal machinery that
post-translationally modify the core peptide (Figure 5.2). Presence of tailoring enzymes
and their putative activities are often shared among related BGCs. However, the predicted
functions of most tailoring enzymes have not been validated and the extent of lasso peptide
modification beyond the lariat knot is unclear [147, 157]. Furthermore, the presence of BGCs
with different conserved sets of tailoring enzymes implies the potential of different functional
classes of lasso peptides. Exploring this diversity is critical to understanding lasso peptide
structure and function.
Clade 2 is comprised of Proteobacteria, Sphingomonadaceae, Caulobacteracea and
Xanthomonadaceae species, which possess a conserved isopeptidase (COG1506) [170]. A
similar enzyme from the lasso peptide BGC in Asticcaucalis benevestitus was found to
catalyze macrolactam ring opening of the mature lasso peptide [171]. Isopeptidase activity
has been described towards several lasso peptides and recognition is based upon topology
Table 5.1: Overview of 3 clades of lasso peptide biosynthetic gene clusters identified.







Clade 1 12 5 0% 0% 0% 0%
Clade 2 27 0 0% 0% 0% 78%
Clade 3 41 1 90% 80% 29% 0%
Total 80 6 46% 41% 15% 26%
72
and not sequence; however, the biological function of this interaction remains enigmatic
[172, 173].
The third clade encompasses most of the lasso peptide BGCs identified in this collection
including 28 clusters from Firmicutes, 5 clusters from Bacteriodetes and 8 clusters from
α-Proteobacteria. Most of these clusters contain a kinase enzyme (SSF53795) [174] and
frequently an uncharacterized nucleotide transferase (pfam 14907) [175]. Recently, a similar
enzyme was described with kinase activity towards the lasso precursor peptide C-terminal
serine [157]. This lasso peptide, paeninodin, is phosphorylated by the putative kinase prior
to cyclization and leader peptide cleavage. The C-terminal serine can be phosphorylated
several times in vitro; however, this peptide modification state has not been observed in
vitro [176]. While the function of this modification is unclear, the presence of other conserved
transferases in the gene neighborhood of paeninodin-like peptides suggests that the observed
phosphorylation is part of a larger tailoring process that provides function. Intriguingly, 12
clusters from Paenibacillaceae contained a conserved sulfotransferase domain (pfam 13469)
that has not previously been observed in lasso peptide BGCs. .
5.4.2 MALDI-TOF-MS screen for lasso peptides.
The presence of a lasso peptide BGC in a genome does not indicate that the corresponding
metabolite is produced; often, NP BGCs are cryptic and must be activated or expressed
in a heterologous host. In the case of lasso peptides, many systems require heterologous
expression [177]. However, unlike predicted structures from genomic data, natively expressed
NPs provide information about the structure of a fully mature product. To survey the extent
of lasso peptide expression and modification without the presence of community members,
individual isolates were screened for constitutively expressed lasso peptides.
In brief, bacteria were grown in liquid media to stationary phase, and the cells were
extracted with methanol. Samples were analyzed by MALDI-TOF-MS for the presence of
lasso peptide masses as predicted by the lasso peptide prediction program RODEO [147]. In
a preliminary screen, masses +/- 25 m/z different from the predicted mass were identified
in 8 bacterial isolates; the associated spectra are cataloged in (Supplemental Figure 5.9).
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Figure 5.3: MALDI-TOF mass spectra of product from PDC88. Masses of interest are
labeled.












Linear Core 2548.198 2549.206 - 2549.852 -0.646
Cyclized 2530.188 2531.195 - 2534.065 -2.870
Sulfated PDC88
Linear Core 2628.155 - 2651.145 2649.055 2.090
Cyclized 2610.140 - 2633.130 2632.820 0.310
Phosphorylated PDC88
Linear Core 2628.165 - 2651.154 2649.055 2.099
Cyclized 2610.154 - 2633.144 2632.820 0.324
74
Amongst the nine identified peptides; six were from clade 1, two from clade 2 and one
from clade 3. The single peptide from clade 3 was produced by Paenibacillus sp. PDC88. In
addition to the two masses which approximate the linear (2549.85 Da) and cyclized PDC88
peptide (2534.07 Da), a pair of masses approximately 100 Da greater than the predicted linear
and cyclized peptide were detected (Figure 5.3). Based upon the presence of a kinase and
putative sulfotransferase enzyme in the gene neighborhood of the PDC88 lasso cyclase, these
additional peaks were hypothesized to be associated with the linear and cyclized sodiated
mass of a tailored PDC88 lasso peptide. Phosphorylation and sulfation of hydroxyl groups
cause similar changes in molecular mass, resulting in an increase in the monoisotopic mass
of 79.966 m/z and 79.956 m/z, respectively (Table 5.2). Due to the high background in
the methanolic extracts and low peak resolution, the identity of this modification could not
be determined. To determine the plausibility of a sulfation occurring on the PDC88 lasso
peptide, the peptides and gene neighborhoods of clade 3 were further analyzed.
5.4.3 Sequence analysis of precursor peptides in clade 3.
As the discovered sulfotransferase has not previously been associated with lasso peptide
biosynthesis, we investigated the similarity between the 12 sulfotransferases and the putative
lasso peptide kinases and nucleotide transferases found in the collection to search for shared
recognition or substrate binding pockets. A sequence similarity network (SSN) was generated
comparing all of the transferases to each other (Figure 5.4) [164]. At a low alignment score
threshold (10−20), nucleotidyltransferases from Firmicutes and Proteobacteria and kinases
from Firmicutes, Proteobacteria and a member of Bacteriodetes cluster together, potentially
due to their shared functional domain, but at a higher threshold (10−60) the across-class
clustering falls apart. Amino acid sequence motifs were identified with MEME [166]; several
sequence motifs were identified within each group of transferase, but no motifs were found
across all transferases (Supplemental Table C-2). No shared peptide recognition or
binding domains were identified on the transferases; however, the lack of a shared recognition
domain on the essential proteins for lasso peptide maturation suggests this is not required
for activity [149].
75
Figure 5.4: Sequence similarity network (SSN) for lasso peptide tailoring transferases in
clade 3. Edge lengths are proportional to the percent sequence identity shared between each
node. Networks are shown at two alignment thresholds (e=10−60 and e=10−20). Nodes are
labeled with a unique isolate identifier and a cluster number. Nodes are labeled with a unique
isolate identifier and a cluster number if more than one cluster is present in genome. Nodes
are colored according to class: Firmicutes, purple; Bacteriodetes, orange; Pproteobacteria,
blue.
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Lasso peptide cyclization is mediated by a RRE sequence found on the B or E protein
(Figure 5.1). However, C-terminal phosphorylation of paeninodin proceeds in the absence of
the leader peptide, albeit with decreased efficiency [157]. This suggests sequence motifs that
guide post-translational modification could exist on either the leader or core peptide [178].
Peptide sequence motif analysis was carried out on all lasso peptides within clade 3 to identify
potential shared or novel recognition sequences for the tailoring enzymes. Sequence motifs
were found to be shared among peptides from different classes (Figure 5.5A). Specifically,
a conserved N-terminal motif is shared with nearly every member of clade 3 (Figure 5.5B);
this is likely the recognition sequence for the RRE [149]. Motifs 2 and 3 do not appear
together on any peptide; the conserved Asp residues in the 5 position of motif 2 and the
7 position in motif 3 suggests there may be at least two different lasso ring sizes formed
within this clade. Additionally, the acidic residues -2 and -4 from a conserved tyrosine in
motif 2 resemble the site for tyrosine o-sulfation found in other organisms [179]. Motif 2 is
present in 83% of the peptides with a sulfotransferase in their gene neighborhood, including
PDC88. Given the possibility that PDC88 could be phosphorylated or sulfonated, and the
precursor peptide contains a probable sulfation motif, a synthetic method based upon CFPS
was developed to investigate the potential sulfation of a lasso peptide.
Figure 5.5: A. Neighbor joining tree of the lasso cyclases of clade 3. Sequence motifs
identified in the precursor peptides found in the associated gene neighborhood are represented
as three colored arrows. Clusters containing a sulfotransferase are marked with a star. B. Key
with the LOGOs for the three lasso peptide precursor amino acid sequence motifs identified
by MEME and shown in panel A.
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5.4.4 Cell-free protein synthesis of functionalized lasso peptides.
Often RiPP biosynthetic enzymes and precursor peptides are expressed in heterologous hosts
and purified for in vitro enzyme assays to determine their activities and end products. in vitro
transcription and translation of proteins and peptides is an alternative that minimizes cloning
and purification, is amenable to production of cytotoxic products, and allows modification of
expression conditions [127]. While CFPS of functional enzymes is routine, small peptides are
not often synthesized in vitro. Two well-described lasso peptides, microcin J25 and klebsidin
[155], two cell-free systems, the E. coli crude S30 lysate [120] and the PURE system [180],
were investigated for their ability to produce mature lasso peptides. In brief, the precursor
peptide and the minimal maturation enzymes were expressed together in each cell-free system
and the products were analyzed by LC-MS/MS with untargeted peptide sequencing.
Lasso peptide precursors go through several intermediates on their way to maturation,
although the intermediates have not been observed from native hosts or in heterologous
expression systems. Untargeted peptidomics enables monitoring of all modifications to the
precursor prior to cyclization and is a high-throughput method to assess production of novel
RiPPs. Neither full length precursor peptide was observed in either expression system, but
smaller peptides were detected and sequenced for microcin J25 in both cell-free expression
systems and klebsidin in the PURE system (Figure 5.6A). Peptide coverage was highest in
the PURE system; each amino acid of the klebsidin peptide detected, including masses for the
full length klebsidin core peptide (Supplemental Figure 5.10). The S30 system performed
less well; only amino acids N8-G39 were detected for microcin J25 and no klebsidin peptides
were detected. Neither of the mature lasso peptides were observed using either expression
system.
Prompted by the low precursor peptide production in both systems, a fully synthetic
precursor peptide was used instead of one produced in situ to investigate the tailoring
enzymes of PDC88. Peptide coverage was much improved with a synthetic peptide (Figure
5.6B) however, reaction clean up using size exclusion filters reduced peptide coverage and
the length of peptides detected. The molecular weight cutoff of size exclusion filters (10 kDa)
assumed a globular protein, but linear peptides, even those much smaller than the cutoff, can
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Figure 5.6: Schematic of CFPS of lasso peptides and average spectral counts for each
amino acid position as determined by untargeted LC-MS/MS. Leader peptides are colored
red, predicted macrolactam ring is colored orange and the peptide tail region is colored blue.
A. Expression of control precursor peptides (n≥2) klebsidin (KlebA) in PURE system (top
panel) and microcin J25 (McjA) in the PURE system (middle panel) and the crude S30
lysate (bottom panel). No klebsidin peptides were produced by CFPS in crude S30 lysate.
Linear DNA templates were used for PURE system CFPS and plasmid DNA templates were
used for crude S30 lysate CFPS. B. Changes in synthetic PDC88 precursor peptide as a
result of incubation with PURE system without (middle panel) and with (bottom panel)
DNA template for maturation enzymes. Linear DNA templates for PDC88 B, C, and E
proteins were used for maturation study (n≥2) in PURE system.
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be retained by the filter. Use of reverse-phase C18 columns led to increased peptide coverage
and observed peptide sequence length, although the column functionalization can irreversibly
bind some mature lasso peptides (unpublished data). More importantly, modifications that
occur prior to cyclization are detectable with this method.
Incubation of synthetic PDC88 precursor peptide with the PURE expression system
and without DNA template for the maturation enzymes resulted in decreased detection of
peptide, particularly at the N-terminus (Figure 5.6B). Reduction in total peptide yield
is likely decreased due to background proteins in the PURE system interfering with C18
column binding or ion suppression [181]. However, the decreased coverage of the N-terminus
suggests that peptide degradation may be a factor even in a minimal expression system
with no known proteases. Spontaneous cleavage and peptide hydrolysis has been observed
in relatively mild conditions [182]. The increased prevalence of the lasso peptide tail (W32-
S44) suggests that the tail region may be resistant to proteolysis even prior to modification.
However, this complicates assessment of leader peptide cleavage when post-translational
enzymes are present, as no additional enrichment of the lasso core region or total peptide
coverage was observed when the DNA template for maturation enzymes was added to the
reaction.
Computational tools exist that compare MS/MS spectra to characterized compounds,
such as Dereplicator+, but application of this tool did not result in identification of lasso
peptides in any experiment in this study [183]. Current untargeted MS/MS methods struggle
to identity cyclic peptides due to their generally non-predictable fragmentation patterns
[184]. However, targeted MS identified masses (mass error ≤ 5 ppm) corresponding to the
core and cyclic PDC88 lasso peptides when synthetic precursor was incubated with all three
maturation enzymes (Supplemental Figure 5.11, Figure 5.7A). XICs were prepared and
the resulting MS2 fragments were sequenced with PEAKSX [185]. The sequence of the linear
peptide was confirmed (Supplemental Table 5.4); however, the ion corresponding to the
cyclized lasso peptide mass was a false positive. Peptide sequencing revealed a dehydration
to Asp39 instead of ring formation (Table 5.3, Figure 5.7B). It is possible the observed
dehydration is the result of a reversible ring formation with Asp39. However, a 17 member
macrolactam ring is significantly larger than any previously observed lasso peptide ring;
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Figure 5.7: Analysis of potential cyclized PDC88 synthetic peptide when incubated with
maturation enzymes. A. MS spectra of PDC88 synthetic peptide; top panel, total ion
chromatogram of PDC88 synthetic peptide incubated with maturation enzymes; middle
panel, extracted ion chromatogram of dehydrated PDC88 core ([M+3H-18.0152]3+, 844.4032
Da, 10 ppm window); lower panel, full MS scan at peptide elution (retention time = 121.09
min). B. MS2 spectrum of 844.4025 Da parent ion annotated with PEAKSX. Error map
displayed under each annotated b and y ion.
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Table 5.3: Identified b and y ions identified in MS/MS spectra using PEAKSX for synthetic
peptide PDC88 parent mass (844.4025 Da).
b ion # b b (2+) Amino acid seq y y-H20 y-NH3 y ion #
1 - - K - - - 22
2 - - G - - - 21
3 - - V - 2328.08 - 20
4 - - G - - - 19
5 - - Y - - - 18
6 - - R - - - 17
7 - - Q - - - 16
8 - - I - - - 15
9 1017.54 - D - - - 14
10 1203.62 - W - - - 13
11 1316.71 - I - - - 12
12 - - S - - - 11
13 1532.79 - E - - - 10
14 - - H - - - 9
15 - - D - - - 8
16 - - G - - - 7
17 1938.91 969.96 D(-18.01) - - - 6
18 2052.00 - L - - - 5
19 2215.05 1108.03 Y - - - 4
20 2329.11 1165.05 N 317.15 299.14 300.11 3
21 - - P 203.10 - - 2
22 - - S - - - 1
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the average lasso peptide ring is seven to nine residues [147]. Incubation of the synthetic
precursor peptide with the PURE system and DNA template for the sulfotransferase did
not result in identification of a sulfation. Inclusion of the full set of maturation enzymes in
the reaction also did not yield a sulfation. Furthermore, sulfation of the C-terminal Ser44
or Tyr41 was not detected in targeted methods, suggesting that sulfation does not occur on
the unmodified C-terminus of PDC88.
Untargeted peptide sequencing enabled measurement of peptides synthesized by CFPS
despite suboptimal production levels and interfering degradation processes. Targeted MS
methods alone failed to identify any peptides produced by CFPS due to unanticipated
truncations of the precursor. Additionally, differences in peptide coverage observed by
this method revealed that implementation of purification techniques will be critical to
characterization of lasso peptides. Nevertheless, a fully mature lasso peptide with or without
sulfation was not detected by any method. This indicates that further development of
cell-free production of small peptides in combination with in vitro lasso peptide cyclization
methodologies and tandem MS/MS of peptide NPs is required for exploration of lasso peptide
diversity and eventually functionality.
5.5 Conclusion
Newly developed genome mining tools have rapidly increased the number of gene sequences
of predicted NPs, particularly for previously elusive classes with unusual BGC architectures
like RiPPs. Although the lasso peptide cluster appears to be prevalent in the Populus root
microbiome, with over eighty clusters from 407 organisms and spread across three bacterial
clades, the function of lasso peptides in plant-microbe interactions remains elusive.
Analysis of lasso peptide BGCs revealed 12 clusters containing an enzyme with predicted
sulfotransferase activity previously unknown to be associated with neither predicted nor
characterized lasso peptides. Through constitutive expression screening, sequence similarity
analysis, and amino acid motif identification, this enzyme was predicted to perform a novel
sulfation on the C-terminus of 10 lasso peptides in this collection. To investigate this function
and explore the chemical and structural diversity of lasso peptides, a synthetic methodology
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combining CFPS and untargeted peptide sequencing by LC MS/MS was developed. Though
a novel sulfation was not identified with this method, its development identified critical
research areas for advancing high-throughput in vitro functional genomics.
Enzymatic generation of small molecule diversity will be greatly served by the develop-
ment of a high-throughput method for screening the many unknown tailoring enzymes in the
BGCs of lasso peptides and other RiPPs. The combination of CFPS of tailoring enzymes
and precursor peptides with untargeted peptide sequencing enables rapid determination of
peptide modifications and reaction order. Challenges remain in robust production of small
peptides, particularly in crude extracts. Peptide production was adequate in the PURE
system but was still limited by non-specific degradation. However, recent progress in the
development of crude CFPS expression systems from Vibrio natriegens suggest high yield in
vitro peptide synthesis is possible [186]. Untargeted peptide sequencing will be a necessary
analytic tool for engineering improved peptide synthesis using CFPS.
Database-independent MS methods for discovery of post-translational modification has
improved alongside mass accuracy and computational power, but cyclic peptide structures
remain difficult to decipher due to the multiple possible peptide sequences that result from
fragmentation. Most current discovery methods rely on spectra matching to databases of
curated peptides, which limits rediscovery [187], but is less robust towards finding novel
peptidic NPs whose post-translational modifications and final structures are not known.
However, as more cyclic peptides are characterized, spectral libraries will become more
broadly useful and untargeted approaches will more easily deconvolute new data [188, 184].
Existing heterologous expression workflows cannot keep up with the boom in high-quality
genome sequence data. Predictive and computation tools can provide partial information
about many ORFs but are not a substitute for empirical data. High-throughput cell-free
expression studies are becoming a promising tool for functional genomics efforts and NP
discovery, but often need to be engineered for specific products [117]. Incorporation of mass
spectroscopy-based omics techniques into the engineering process for cell-free systems will




Figure 5.8: Phyla of 407 sequenced isolates. Isolate identities are described in
Supplemental Table C-1.
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Figure 5.9: MALDI-TOF mass spectra of each potential product identified from an isolate.
Masses of interest are labeled. A. PDC88 predicted mass 2531.2 Da, observed mass 2539.970
Da. B. YR128 predicted mass 1742.9 Da; observed mass 1742.595 Da. C. YR375 predicted
mass 1619. Da7; observed mass 1641.940 Da. D. CF124 predicted mass 1639.9 Da, observed
mass 1662.491 Da. E. OK461 predicted mass 2166.9 D, observed mass 2185.990 Da. F.
OK228 predicted mass 2165.9 Da, observed mass 2186.643 Da. G. OV198 predicted mass
2166.9 Da, observed mass 2187.296 Da. H. OK006 predicted mass 2166.9 Da, observed mass
2186.251 Da.
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Figure 5.10: MS spectra for klebsidin. Top panel, extracted ion chromatogram of klebsidin
core ([M+2H]2+, m/z = 1025.9650, 10 ppm window); lower panel, full MS scan at peptide
elution (retention time = 118.61 min).
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Figure 5.11: Analysis linear core PDC88 synthetic peptide when incubated with maturation
enzymes. A. Total ion chromatogram (top panel), extracted ion chromatogram (middle
panel), and full MS scan at peptide elution time (rt = 118.61 min) (lower panel) of the
PDC88 synthetic peptide incubated with maturation enzymes ([M+3H]3+, m/z = 850.4061,
10 ppm window). B. MS2 spectrum of the 850.4055 Da parent ion annotated with PEAKSX.
Error map displayed under each annotated b and y ion.
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Table 5.4: Identified b and y ions for PDC88 synthetic peptide parent mass (850.4055 Da),
identified in MS/MS spectra using PEAKSX.
b ion # b b-H20 b (2+) Amino acid seq y y-H20 y-NH3 y ion #
1 - - - K - - - 22
2 - - - G - - - 21
3 - - - V - - - 20
4 - - - G - - - 19
5 - - - Y - - - 18
6 - - - R - - - 17
7 - - - Q - - - 16
8 - - - I - - - 15
9 1017.55 - 509.28 D - - - 14
10 1203.61 - - W - - - 13
11 1316.7 - - I - - - 12
12 - - - S - - - 11
13 1532.79 - - E - - - 10
14 - - - H - - - 9
15 1784.86 - - D - - - 8
16 - - - G - - - 7
17 1956.92 978.96 D - - - 6
18 - - 1035.51 L - - - 5
19 2233.05 - 1117.03 Y - - - 4
20 2347.11 2329.09 1174.06 N 317.15 299.14 300.12 3
21 - - - P 203.1 - - 2




Genome mining and functional prediction are powerful tools for the identification of novel NP
pathways but must be paired with empirical validation. Engineering heterologous expression
of NP gene clusters is low-throughput and production can be limited by cytotoxicity and
the metabolic demands of growth-related processes. Alternatively, cell-free systems are a
high-throughput method for the expression and characterization of peptides, enzymes and
metabolic pathways.
Both the engineering and application of cell-free systems are aided by global analytic
measures. Particularly, the utility of proteomics as an analytic method for cell-free protein
synthesis in crude lysates cannot be overstated, as it can provide assessment of both in
vitro expression levels and quantitative measures of the abundance of transcriptional and
translational machinery [68]. In this thesis, the benefits of untargeted peptidomics were
apparent across three cell-free systems, demonstrated by its value in evaluating enzyme
activity and observing systemic impacts of growth media composition on lysate metabolic
potential.
The number of newly discovered gene clusters expected to produce peptide NPs greatly
outnumbers the described members of this class. Cell-free protein and peptide synthesis
is particularly well-suited to the characterization of new RiPP BGCs. Through the
investigation of a novel putative sulfotransferase, untargeted peptidomics was critical in
measuring not only full-length peptide products, but also intermediates, partially translated
peptides, and degraded products. The degradation of peptides, even in a purified system with
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no known peptidases, was observed through these methods. The use of this tool is paramount
in both the discovery of new peptide NPs and the improvement of in vitro peptide synthesis.
Systematic engineering of cell-free systems will broaden the organismal diversity from which
lysates are derived and will provide access to new functions in vitro. Already, early work on
cell-free protein synthesis in Streptomyces and Vibrio species show increased yields of high
G-C content proteins and short peptides, respectively [189, 190, 186].
Demonstrating its utility beyond measurement of individual peptide abundance, detec-
tion of global protein abundance by assembled peptidomics revealed the presence of protein
families in the S30 lysate that were expected to be absent after cell lysis. Particularly,
the identification of components of the phosphotransferase system (PTS) within crude E.
coli cell extracts raises questions about the fate of sugar substrates and the depletion of
phosphenolpyruvate as a result of the activity of PTS. Identification of these functions
serves not only exploration of the metabolic malleability of organisms, but also facilitates
the engineering of cell-free systems.
Illumination of the black box of crude cell-free systems with proteomics enables their
engineering. The impacts of modifications to media and preparation conditions can have
large impacts on protein content; however, guided by proteomics, these modifications can
be leveraged to improve cell-free biosynthetic processes. To improve in vitro tyrosine
biosynthesis, the effects of four changes to growth media for a crude S30 E. coli lysate
were assessed with shotgun proteomics. Combining the modifications which upregulated
proteins of interest more than doubled yield. Expression of a feedback insensitive variant
of a rate-limiting enzyme by CFPS further grew yield, demonstrating the strengths of a
combined cell-free protein synthesis and metabolic engineering platform.
Removed from the cellular milieu, biochemical processes are both simplified and more
versatile in their applications than their cellular counterparts. However, wide-spread
adoption of crude cell-free systems for metabolic engineering and functional genomics is
hampered by the inherent complexity of a system derived from living cells. In addition to
the large biological variability between and within populations of cells, numerous variables
in extract preparation including lysis efficiency and cellular life stage make standardization
of crude cell-free systems challenging. Post-lysis benchmarking and adjustment of the
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components of cell-free systems may be a more tractable method to increase reproducibility.
Identification of critical metabolites or proteins that are predictive of in vitro activity
will be necessary to reduce the variability between cell-free systems. Furthermore, the
post-translational modification of enzymes within crude lysates and the lability of these
modifications in vitro remains an unexplored source of variability in cell-free systems
that may significantly influence metabolic activity and the efficiency of protein synthesis
[191, 192]. Controlling this complexity through engineering guided by global analytic tools
will increase the reproducibility and the reliability of cell-free systems for both protein
synthesis and metabolite production.
Reliability and reproducibility will be central to future development of CFPS platforms,
but the current performance of these systems has been sufficient to allow wide-spread
adoption of CFPS as a tool for investigating enzyme function and diversity. However, the use
of CFPS to produce consumable biomolecules has been limited to pilot studies on the micro-
scale, due to a combination of inadequate protein yield and the need for expensive substrates.
Implementation of promising genetic and computational tools will aid improvement of in
vitro protein yield through post-lysis modification of lysates and enable the engineering
of phenotypes derived from interactions of tens of enzymes [47, 140, 139, 130]. The cost
of substrates, including amino acids, tRNAs, nucleosides, and DNA templates currently
limit the scalabiltiy of CFPS. Reducing reliance on exogenous substrates by capturing the
metabolites present during lysis and activation of endogenous salvage and recycling pathways
could greatly reduce the cost of in vitro protein synthesis. Additionally, further development
of CFPS systems capable of using a linear DNA template are of great interest as PCR is a
scalable and inexpensive source of template DNA. A high-yield and low-cost CFPS system
would enable the on-demand production of customizable antibodies, enzyme therapeutics
and peptide drugs.
In contrast to CFPS systems, crude lysates and other multi-enzyme reaction cascades
which have undergone varying degrees of purification are common tools for carrying out
large-scale industrial processes in the fine and commodity chemical industries [193, 194, 195].
Often individual enzymes are rationally-engineered or evolved to improve productivity. As
the length of metabolic pathways of interest has increased, CFPS has been introduced as a
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tool in these workflows to accelerate design-build-test cycles. Combined CFME-PS systems
are primarily a prototyping platform for eventual in vivo bioproduction, due to substrate
costs; however, use-cases exist particularly in scenarios where biocontainment and production
of numerous diverse compounds are of value. Unlike living cells, genomic DNA is unnecessary
for cell-free processes, which eases the requirements for their release into the environment.
Building from the well-described use of CFPS for sensing of environmental contaminants [196,
197, 198], a cell-free system could be employed to detect and degrade pollutants including
microplastics and pharmaceuticals in water supplies, with limited concerns about release of
genetically-modified organisms. Additionally, the flexibility granted by CFPS would allow
for the development of a lyophilized bioreactor, which could, with the addition of dried
DNA and water, process low-cost sugar substrates to common intermediates that are then
converted to active valuable compounds by enzymes expressed by CFPS.
The value of cell-free systems is predicated on the ability to isolate, investigate and control
complex biochemistries in an environment not limited by organismal constraints. Free from
membranes, cell-free processes like protein synthesis are both efficient and versatile, enabling
rapid synthesis of enzymes from DNA templates. Further, removal of endogenous genetic
material lessens dynamic shifts in protein content and metabolic activity. The combination
of these factors makes cell-free systems a great enabling tool for functional genomics and
metabolic engineering both in vitro and in vivo. Continued development and integration of
cell-free systems and enabling tools will empower biologists to rapidly explore new BGCs
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